<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001990.pub2" GROUP_ID="LUNGCA" ID="583199102112442641" MERGED_FROM="" MODIFIED="2013-11-22 09:25:01 +0000" MODIFIED_BY="Corynne Marchal" NOTES="&lt;p&gt;1. MST= median survival time&lt;/p&gt;&lt;p&gt;2. PR= partial response&lt;/p&gt;&lt;p&gt;3. CR= complete response&lt;/p&gt;" NOTES_MODIFIED="2013-11-22 10:21:33 +0100" NOTES_MODIFIED_BY="Sera Tort" REVIEW_NO=" YAV1" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2013-11-22 10:21:33 +0100" MODIFIED_BY="Sera Tort">
<TITLE MODIFIED="2009-07-06 18:00:30 +0200" MODIFIED_BY="[Empty name]">Chemotherapy versus best supportive care for extensive small cell lung cancer</TITLE>
<CONTACT>
<PERSON ID="14519" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marta</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pelayo Alvarez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>MPelayo@Hospital-Ribera.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Atención Primaria Área 11</DEPARTMENT>
<ORGANISATION>Conselleria Valenciana</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>34-96-2481697</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-11-22 10:19:17 +0100" MODIFIED_BY="Sera Tort">
<PERSON ID="14519" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marta</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pelayo Alvarez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>MPelayo@Hospital-Ribera.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Atención Primaria Área 11</DEPARTMENT>
<ORGANISATION>Conselleria Valenciana</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>34-96-2481697</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="26082754419975949606120627140202" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Virginie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Westeel</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Head of Thoracic Oncology</POSITION>
<EMAIL_1>virginie.westeel@univ-fcomte.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Thoracic Oncology</DEPARTMENT>
<ORGANISATION>University Hospital of Besançon</ORGANISATION>
<ADDRESS_1>3, Boulevard Alexandre Fleming</ADDRESS_1>
<ADDRESS_2/>
<CITY>Besançon</CITY>
<ZIP>25030</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 3 81 66 82 04</PHONE_1>
<PHONE_2/>
<FAX_1>+33 3 81 66 88 11</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BA42C28F82E26AA20158FD700DCCEE14" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Marcela</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cortés-Jofré</LAST_NAME>
<SUFFIX>QF.MSc</SUFFIX>
<POSITION>Clinical Epidemiologist</POSITION>
<EMAIL_1>tutor.mimbe@cochrane.es</EMAIL_1>
<EMAIL_2>p.cortes@ucsc.cl</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Facultad de Medicina, Universidad Católica de la SS. Concepción</DEPARTMENT>
<ORGANISATION>Programa Doctorado en Ciencias Médicas, Universidad de La Frontera</ORGANISATION>
<ADDRESS_1>Av. Costanera 7488, Condominio Bosque Mar Depto. 1003</ADDRESS_1>
<ADDRESS_2>S. Pedro de la P. Concepción</ADDRESS_2>
<CITY>Concepción</CITY>
<ZIP>4030000</ZIP>
<REGION>VIII</REGION>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56412377250</PHONE_1>
<PHONE_2>+56412345441</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D3B1F77E82E26AA200831C1940F4DA2E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Xavier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bonfill Cosp</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>xbonfill@santpau.cat</EMAIL_1>
<EMAIL_2>director@cochrane.es, XBonfill@hsp.santpau.es</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP), Spain - Universitat Autònoma de Barcelona</ORGANISATION>
<ADDRESS_1>Sant Antoni M. Claret 171</ADDRESS_1>
<ADDRESS_2>Casa de Convalescència</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalonia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 291 9527</PHONE_1>
<PHONE_2>+34 93 291 9526</PHONE_2>
<FAX_1>+34 93 291 9525</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-11-07 13:32:35 +0100" MODIFIED_BY="Marta Pelayo Alvarez">
<UP_TO_DATE>
<DATE DAY="17" MONTH="10" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="10" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="10" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-11-22 10:21:33 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-11-22 10:21:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>The review has been updated but conclusions have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-14 13:04:24 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>A new search was run and a new trial was identified in second-line chemotherapy at relapse, but conclusions did not change.</P>
<P>Some co-authors have changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-04-08 10:14:08 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-04-08 10:14:00 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact author changed as well as some co-authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-08 10:14:08 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>First-line chemotherapy versus best supportive care or placebo is an update from the 2003 review. Second-line chemotherapy versus best supportive care in patients at relapse or progression has been added as a new objective. Searches were run, two new studies were identified but conclusions did not change.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-02-11 09:16:25 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-02-09 21:32:20 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-02-09 21:32:20 +0100" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-02-11 09:16:25 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-02-09 21:31:08 +0100" MODIFIED_BY="[Empty name]">
<NAME>Instituto Carlos III (Contract no. 10035) Ministry of Health</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>In the initial review of 2003</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-21 19:22:15 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-11-19 19:25:57 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-04-09 12:56:28 +0200" MODIFIED_BY="[Empty name]">Chemotherapy (anticancer drugs) for patients with advanced small cell lung cancer</TITLE>
<SUMMARY_BODY MODIFIED="2013-11-19 19:25:57 +0100" MODIFIED_BY="[Empty name]">
<P>SmalI cell lung cancer accounts for nearly a quarter of all new cases of lung cancer. This cancer is often diagnosed in an advanced stage, which means that it has spread to the brain, liver, bone or bone marrow, and most patients die in the first year after diagnosis. This review found that first-line chemotherapy (anticancer drugs) may prolong the survival of patients with advanced small cell lung cancer for some months when compared to supportive care, although the effect of this treatment on quality of life is unknown. The benefit of a new treatment (second-line chemotherapy) when the disease has progressed or relapsed was even smaller, and the potential survival gain of some weeks must be balanced against its possible secondary effects. Since the available studies were scarce and of variable quality, more clinical trials are needed to assess and better inform patients about the real effectiveness of chemotherapy in advanced small cell lung cancer.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-21 18:52:28 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Combination chemotherapy has been the mainstay of treatment for extensive stage small celI lung cancer (SCLC) over the last 30 years, even though it only gives a short prolongation in median survival time. The main goal for these patients should be palliation with the aim of improving their quality of life.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-11-11 16:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of first-line chemotherapy versus placebo or best supportive care (BSC) in prolonging survival in patients with extensive SCLC at diagnosis and the effectiveness of second-line chemotherapy at relapse or progression after first-line chemotherapy compared with BSC or placebo in prolonging survival in patients with extensive SCLC; as well as to evaluate the adverse events of treatment and the quality of life of patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-11-11 16:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>This is the second update of the review. MEDLINE (1966 to October 2013), EMBASE (1974 to October 2013), and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 3) were searched. Experts in the field were contacted.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Phase III randomised controlled trials in which any chemotherapy treatment was compared with  placebo or BSC in patients with extensive SCLC, as first-line or second-line therapy at relapse.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-27 12:10:29 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data and assessed study quality. We resolved disagreements by discussion. Additional information was obtained from one study author.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-11-21 18:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies of unclear risk of bias were included for first-line chemotherapy. A total of 88 men under 70 years with good performance status were randomised to receive either supportive care, placebo infusion or ifosfamide. Ifosfamide gave an extra mean survival of 78.5 days compared with supportive care or placebo infusion. Partial tumour response was greater with the active treatment. Toxicity was only seen in the chemotherapy group and quality of life was only assessed at the beginning of treatment. The quality of the evidence for overall survival and adverse effects was very low.</P>
<P>Three studies of moderate risk of bias were included for second-line chemotherapy at relapse (one identified in the last search). A total of 932 men and women under 75 years and any performance status were randomised to receive either methotrexate-doxorubicin, topotecan, or picoplatin versus symptomatic treatment or BSC. The methotrexate-doxorubicin treatment gave a median survival of 63 days longer than in the symptomatic-treatment group for patients allocated to receive four cycles of first-line chemotherapy, and 21 days longer for patients allocated to receive eight cycles of first-line chemotherapy.</P>
<P>Treatment with topotecan gave a median survival of 84 days longer than in the BSC group (log-rank P = 0.01). The adjusted hazard ratio (HR) for overall survival was 0.61 (95% CI 0.43 to 0.87). Treatment with picoplatin gave a median survival time of six days longer than BSC (HR 0.817, 95% CI 0.65 to 1.03, P = 0.0895). A meta-analysis of topotecan and picoplatin gave a HR of 0.73 (95% CI 0.55 to 0.96, P = 0.03; low-quality evidence).</P>
<P>Partial or complete response in the methotrexate-doxorubicin group was 22.3%. Five patients (7%, 95% CI 2.33 to 15.67) showed a partial response with topotecan. No data were provided about tumour response in the picoplatin study. Toxicity was worst in the chemotherapy group (moderate-quality evidence). Quality of life was better in the topotecan group and was not measured in the methotrexate-doxorubicin and picoplatin studies (low-quality evidence).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-11-21 18:52:28 +0100" MODIFIED_BY="[Empty name]">
<P> Two small RCTs from the 1970s suggest that first-line chemotherapeutic treatment (based on ifosfamide) may provide a small survival benefit (less than three months) in<B> </B>comparison with supportive care or placebo infusion in patients with advanced SCLC. However platinum-based combination chemotherapy regimens have been shown to increase complete response rates when compared to non-platinum chemotherapy regimens with no significant difference in survival, and so these are currently the standard first-line treatment for patients with SCLC.</P>
<P>Second-line chemotherapy at relapse or progression may prolong survival for some weeks in relation to BSC. Nevertheless, the impact of first-line chemotherapy on quality of life, older patients, women and patients with poor prognosis is unknown and the benefits of second-line chemotherapy are also unclear for older people. Globally, the evidence on which these conclusions are based is very scarce and of uncertain or low quality, which calls for well-designed, controlled trials to further evaluate the trade-offs between benefits and risks of different chemotherapeutic schedules in patients with advanced SCLC.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-21 19:22:15 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-11-17 19:30:34 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-11-17 19:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Small cell Iung cancer (SCLC) accounts for 15% to 17% of new cases of lung cancer among males and females respectively (<LINK REF="REF-Riaz-2012" TYPE="REFERENCE">Riaz 2012</LINK>), with a gradual decline in the proportion of male patients compared to female patients in the last two decades. Women comprised 28% of all cases in 1973 yet by 2002 this proportion had risen to 50% (<LINK REF="REF-Weatley_x002d_Price-2010" TYPE="REFERENCE">Weatley-Price 2010</LINK>). As a result of increasing life expectancy, about 32% of newly diagnosed SCLC cases occur in patients older than 70 years of age and 10% of cases are diagnosed in patients older than 80 years of age (<LINK REF="REF-Owonikoko-2007" TYPE="REFERENCE">Owonikoko 2007</LINK>). Early diagnosis of SCLC is uncommon. Between 60% and 70% of patients have extensive disease at diagnosis with metastases involving one or more sites, such as the brain, liver, bone or bone marrow (<LINK REF="REF-Carney-2002" TYPE="REFERENCE">Carney 2002</LINK>). Untreated SCLC is lethal within two to three months of diagnosis in most patients, and survival beyond one year is rare (<LINK REF="REF-De-Vita-2000" TYPE="REFERENCE">De Vita 2000</LINK>; <LINK REF="REF-Vrdoljak-2001" TYPE="REFERENCE">Vrdoljak 2001</LINK>; <LINK REF="REF-Zelen-1973" TYPE="REFERENCE">Zelen 1973</LINK>). The majority of patients with extensive disease will relapse after treatment, usually within the first year after diagnosis. The two-year cumulative recurrence rate is 75% in patients with limited disease and nearly 100% in patients with extensive disease. The lungs are the most frequent site of initial recurrence, followed by the liver, bone, and the brain (<LINK REF="REF-Gralla-2004" TYPE="REFERENCE">Gralla 2004</LINK>; <LINK REF="REF-Sugiyama-2008" TYPE="REFERENCE">Sugiyama 2008</LINK>). Local treatments such as resection and radiotherapy have a limited effect on advanced disease (<LINK REF="REF-Souhami-1990" TYPE="REFERENCE">Souhami 1990</LINK>) so the most widely accepted option for treating advanced SCLC is chemotherapy. Current evidence does not support screening for lung cancer with any modality, including chest radiography, sputum cytology, or spiral computed tomography (<LINK REF="REF-Manser-2010" TYPE="REFERENCE">Manser 2010</LINK>). There is no evidence either for recommending vitamin supplements for the prevention of lung cancer (<LINK REF="REF-Cort_x00e9_s_x002d_Jofr_x00e9_-2012" TYPE="REFERENCE">Cortés-Jofré 2012</LINK>).</P>
<P>The effect of chemotherapy with single agents was evaluated in controlled studies by the Veteran Administration Lung Group, which showed the effectiveness of cyclophosphamide in the treatment of SCLC when compared with placebo (<LINK REF="STD-Green-1969" TYPE="STUDY">Green 1969</LINK>). Following on from these studies, combination chemotherapy became the mainstay of treatment for patients with extensive-stage SCLC in the 1970s (<LINK REF="REF-Ihde-1992" TYPE="REFERENCE">Ihde 1992</LINK>). In the 1980s, the most widely used combination of drugs for initial treatment of extensive-stage SCLC was cyclophosphamide, doxorubicin, and vincristine, which produced partial or complete tumour remissions in 50% to 85% of patients and increased the median survival time by between nine and 12 months in unselected patient groups (<LINK REF="REF-De-Wet-1994" TYPE="REFERENCE">De Wet 1994</LINK>; <LINK REF="REF-Hollen-1994a" TYPE="REFERENCE">Hollen 1994a</LINK>; <LINK REF="REF-Hollen-1994b" TYPE="REFERENCE">Hollen 1994b</LINK>; <LINK REF="REF-Oze-2009" TYPE="REFERENCE">Oze 2009</LINK>; <LINK REF="REF-Souhami-1990" TYPE="REFERENCE">Souhami 1990</LINK>). In the late 1980s, a combination regime of cisplatin and etoposide was introduced. Despite diverse strategies for the treatment of these patients, the results of phase III trials over the past 30 years have shown only a two month prolongation in median survival time for patients treated with different regimens (<LINK REF="REF-Chutte-1999" TYPE="REFERENCE">Chutte 1999</LINK>), or a 0.021 month (0.63 day) increase in median survival time per year (<LINK REF="REF-Oze-2009" TYPE="REFERENCE">Oze 2009</LINK>), with 5% to 10% surviving two years and only 1% of patients achieving long-term disease-free survival (<LINK REF="REF-Govindan-2006" TYPE="REFERENCE">Govindan 2006</LINK>; <LINK REF="STD-Hanna-2002" TYPE="STUDY">Hanna 2002</LINK>; <LINK REF="REF-Lassen-1998" TYPE="REFERENCE">Lassen 1998</LINK>; <LINK REF="REF-Wolf-2004" TYPE="REFERENCE">Wolf 2004</LINK>). Overall, women have had a significantly longer median survival than men (<LINK REF="REF-Weatley_x002d_Price-2010" TYPE="REFERENCE">Weatley-Price 2010</LINK>). The lowest survival rates are in the very elderly, 80 years or older (<LINK REF="REF-Owonikoko-2007" TYPE="REFERENCE">Owonikoko 2007</LINK>).</P>
<P>A large number of clinical trials comparing different regimens, schedules, and dose intensities of agents have been conducted in advanced SCLC. Comparator regimens have varied greatly between trials, not only with respect to agents but also in dosage, scheduling, and patient and disease factors. The assimilation of findings from this large range of heterogeneous trials is therefore difficult. To date no consistent findings have emerged as to the optimal agent combination or as to the effectiveness of increased dose intensity (<LINK REF="REF-Carney-2002" TYPE="REFERENCE">Carney 2002</LINK>). Recommended treatment regimens have varied with time and at present combinations of platinum are most often indicated for advanced disease (<LINK REF="REF-Seidenfeld-2006" TYPE="REFERENCE">Seidenfeld 2006</LINK>). A recent systematic review of platinum versus non-platinum chemotherapy regimens for SCLC did not find a statistically significant benefit in survival or overall tumour response for platinum-based therapy (<LINK REF="REF-Amarasena-2009" TYPE="REFERENCE">Amarasena 2009</LINK>). However, platinum-based chemotherapy regimens did increase complete response rates, at the cost of higher adverse events. Patients treated with chemotherapy can be categorized as having refractory disease where the disease progresses through first-line treatment; resistance disease, which includes those patients with an initial response to treatment but the disease then progresses within three months of completing treatment; and sensitive disease where patients who have a relapse-free interval of at least three months from completion of treatment receive re-treatment with first-line therapy as the standard approach (<LINK REF="STD-Garassino-2011" TYPE="STUDY">Garassino 2011</LINK>). Second-line chemotherapy offered to patients at relapse may produce tumour regression but the evidence for a clinical benefit is limited. The degree of benefit seems to be related to the type of first-line chemotherapy used, the length of the treatment-free interval, the extent of disease at relapse, and the performance status of the individual (<LINK REF="REF-Sundstr_x00a2_m-2005" TYPE="REFERENCE">Sundstr¢m 2005</LINK>).Thus, until better treatments are developed, the main goal of the therapy for extensive-stage SCLC should be adequate palliation and improvement of overall quality of life.</P>
<P>Our purpose was to review the evidence for the effectiveness of first-line and second-line chemotherapy at relapse or progression in extensive disease SCLC. This is the second update of the review.<BR/>
</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>The purpose of this review was to evaluate the effectiveness of first-line chemotherapy and second-line chemotherapy at relapse or progression after first-line chemotherapy in patients with extensive SCLC compared with best supportive care (BSC) or placebo treatment.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Benefits of first-line or second-line chemotherapy in advanced SCLC patients should include a significantly longer survival than for those treated with best supportive care (BSC) or placebo. The significant improvement in survival should be accompanied by manageable toxicity and an improvement or stabilisation in the quality of life.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>This review of first-line chemotherapy compared with BSC or placebo treatment and second-line chemotherapy at relapse or progression after first-line chemotherapy is the second update of a previous review conducted in 2003 (<LINK REF="REF-Agra-2003" TYPE="REFERENCE">Agra 2003</LINK>) and updated in 2009 (<LINK REF="REF-Pelayo-2009" TYPE="REFERENCE">Pelayo 2009</LINK>). After completion of the original review several questions were raised about future research into the benefits of chemotherapy in extensive SCLC. It was suggested that the feasibility and ethics of undertaking studies comparing active treatment with BSC in patients with poor prognosis should be evaluated. Consideration of the risks and benefits of first and second-line chemotherapy in this subgroup of patients would help to define clearer and more explicit criteria about when to stop chemotherapy or when not to administer second-line treatment with the objective of preserving quality of life. Therefore, the focus of this review is to evaluate chemotherapy compared with BSC in patients with poor prognosis that present with extensive disease at diagnosis or have experienced relapse or progression after first-line treatment. All are patients with an extremely low short-term survival rate.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. To determine the effectiveness of first-line chemotherapy versus placebo or best supportive care (BSC) in prolonging survival in patients with extensive SCLC at diagnosis.</P>
<P>2. To determine the effectiveness of second-line chemotherapy at relapse or progression after first-line chemotherapy compared with BSC or placebo in prolonging survival in patients with extensive SCLC.</P>
<P>3. To evaluate the adverse events of treatment as well as the quality of life of patients with extensive SCLC who were treated with first or second-line chemotherapy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-11 16:07:34 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-07-27 12:10:29 +0200" MODIFIED_BY="[Empty name]">
<P>Phase III randomised controlled trials in patients with extensive stage SCLC. Studies were eligible for inclusion if they were described by the authors as &#8216;randomised&#8217; anywhere in the manuscript.<BR/>There was no language restriction in considering studies eligible for the review.</P>
<P>We excluded phase I and phase II randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Patients of any age with histologically proven SCLC carcinoma staged as extensive or metastatic disease after completion of clinical and diagnostic staging studies. Extensive or metastatic SCLC cancer means that the tumour has spread beyond one hemithorax, including the ipsilateral mediastinal and supraclavicular fossa lymph nodes. All patients with distant metastases were considered to have extensive-stage disease.</P>
<P>For studies of first-line chemotherapy, patients that were included were those that had not received previous treatment (chemotherapy, radiotherapy, hormonal treatment, growth factor, immunotherapy, surgery). For studies of second-line chemotherapy, patients were included if they had received previous chemotherapy treatment and after relapse or progression they received a different chemotherapy regimen. Patients who had received previous radiotherapy, surgery, hormonal treatment, growth factor, or immunotherapy were excluded.<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Studies in which any chemotherapy regimen (any single agent or combination of agents, at any dosage, for any duration or number of cycles) was compared with a control group who received placebo or BSC, and in which there was no concomitant or sequential radiotherapy with curative intention. BSC measures included pain medications and other non-specific palliative treatments (including radiotherapy with explicitly palliative intention, &lt;5 0 Gy) that were intended to palliate a particular symptom.</P>
<P>We excluded studies in which any anticancer treatment other than chemotherapy (radiotherapy or chemoradiotherapy, surgery, hormonal treatment, growth factors, immunotherapy) was compared with either BSC or a placebo intervention.<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>I) Overall survival, measured as the hazard ratio or median or mean values with confidence intervals</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>II) Survival at 6,12, 24 months</P>
<P>III) Complete* and partial** response (see below)</P>
<P>IV) Toxicity, toxic deaths and any other measures of toxicity found to be recorded consistently across studies</P>
<P>V) Quality of life</P>
<P>* Complete response: total disappearance of all known disease for a period of at least four weeks.<BR/>
</P>
<P>** Partial response: in the case of bi-dimensionally measurable disease, a reduction of at least 50% in the sum of the products of the greatest perpendicular diameters measurable or of alI measurable lesions, determined through two observations not more than four weeks apart; in the case of uni-dimensionally measurable disease, reduction of at least 50% in the sum of the greatest diameters of all lesions determined through two observations not more than four weeks apart.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-11-11 16:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised clinical trials and controlled clinical trials on this subject were searched for electronically using MEDLINE (1966 to October 2013), EMBASE (1974 to October 2013), and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 3).<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic searches are detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Identification of further studies from references cited in the initial list of articles</P>
<P>2. We contacted pharmaceutical companies to identify any further unpublished or ongoing trials</P>
<P>3. A search of ongoing trials on the world-wide web: <A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A> and <A HREF="http://www.cancer.gov">www.cancer.gov</A>
</P>
<P>4. A search of grey literature on the world-wide web: <A HREF="http://cadth.ca/resources/grey-matters">http://cadth.ca/resources/grey-matters</A> 
<BR/>

</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed the abstracts of all references identified from the search strategy for inclusion and resolved any disagreements by discussion. We excluded abstracts referring exclusively to limited disease or treatments other than chemotherapy compared with placebo or BSC.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>We entered the trials that met the selection criteria in a specific database. Foreign papers were translated when necessary to allow full assessment. Two authors independently extracted the data from the included studies using a previously standardised and tested form. We resolved discrepancies by discussion. Because most of the studies retrieved by the searches included both patients with limited and extensive disease, we sought specific information about patients with extensive disease from the principal investigators.</P>
<P>To assess the quality of each study we entered the following data in to the database.</P>
<UL>
<LI>Randomisation methods and allocation concealment.</LI>
<LI>Participants: description of patients, age, sex, and performance status.</LI>
<LI>Previous treatment.</LI>
<LI>Interventions: types of drugs and doses, cycles and frequency, other concomitant or sequential treatment, and time of follow-up.</LI>
<LI>Blinding strategies in the follow-up and assessment of the results.</LI>
<LI>Losses to follow-up and use or not of an intention-to-treat analysis.</LI>
<LI>Sample size and how this was determined.</LI>
<LI>Statistical analysis performed.</LI>
<LI>Baseline data.</LI>
<LI>Outcomes: survival time (medians or means at different periods and confidence intervals), complete and partial tumour responses, drug toxicity, and quality of life.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed bias in accordance with The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For each study we considered the following.</P>
<UL>
<LI>Selection bias: systematic differences between baseline characteristics of the comparison groups.</LI>
</UL>
<P>- <B>Sequence generation</B>: a description for allocating interventions to participants based on a random process.</P>
<P>* Low risk of bias: the authors describe a random component in the sequence generation process</P>
<P>* High risk of bias: the authors describe a non-random component in the sequence generation process</P>
<P>* Unclear: there is insufficient information about the sequence generation process to permit judgement of "Low risk" or "High risk"</P>
<P>- <B>Allocation concealment</B>: a description of any method to secure implementation of the random assignments to prevent that allocations could have been foreseen.</P>
<P>* Low risk of bias: the authors describe a central allocation, or sequentially numbered of identical appearance, or sealed envelopes opaque and numbered</P>
<P>* High risk of bias: there is a description of open random allocation, or unsealed or non-opaque envelopes, or alternation, or date of birth</P>
<P>* Unclear: there is insufficient information about the method of concealment to permit judgement of "Low risk" or "High risk"</P>
<UL>
<LI>Performance bias: systematic differences between groups in the care provided or in other factors different from the intervention.</LI>
</UL>
<P>-<B>Blinding of participants and personnel</B>: a description of measures used to blind study participants and personnel for knowledge of which intervention a participant received. Description of any evaluation of effective blinding was also considered. Blinding was considered important for the outcomes of tumour response, toxicity and quality of life, and less important for survival.</P>
<P>* Low risk of bias: blinding of participants and personnel and unlikely that could have been broken, or no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influence by lack of blinding</P>
<P>*High risk of bias: blinding of participants and personnel and likely that the blinding could have been broken with the outcome likely to be influenced by lack of blinding, or no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding</P>
<P>* Unclear: there is insufficient information to permit judgement of "Low risk" or "High risk", or the study did not address blinding</P>
<P>-<B>Blinding of outcome assessors</B>: a description of measures used to blind the assessment of the outcomes</P>
<P>*Low risk of bias: blinding of the outcome assessment and unlikely that the blinding could have been broken, or no blinding but the review authors considered that the outcome measurement is not likely to be influence by lack of blinding</P>
<P>*High risk of bias: blinding of the outcome assessment and likely that the blinding could have been broken with the outcome measurement likely to be influenced by lack of blinding, or no blinding when the outcome assessment is likely to be influence by lack of blinding</P>
<P>*Unclear: there is insufficient information to judge the existence of "Low risk" or "High risk" or the study did not address this kind of blinding</P>
<UL>
<LI>Attrition bias: systematic differences between groups in withdrawals form the study.</LI>
</UL>
<P>- <B>Incomplete outcome data</B>: a description of the level of completeness of each outcome, including withdrawals, dropouts, and protocol deviations. Number of randomised patients in each group and number of evaluated patients with reasons for attrition reported.</P>
<P>*Low risk of bias: any one of the following. No missing outcome data; missing outcome data balanced in number across groups, with similar reasons for missing data; the proportion of missing outcomes compared with the observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate</P>
<P>*High risk of bias: there is reason for missing outcome data likely to be related to the true outcome, with either imbalance in numbers or in reasons for missing data across groups; the proportion of missing outcomes compared with the observed event risk is enough to produce clinically relevant bias in the intervention effect estimate; "as-treated" analysis done with substantial departure of the intervention received form that assigned at randomisation.</P>
<P>*Unclear: there is insufficient information of attrition/exclusions to permit judgement of "Low risk" or "High risk"</P>
<UL>
<LI>Reporting bias: reporting a selection of a subset of the original outcome variables</LI>
</UL>
<P>-<B>Selective reporting</B>:</P>
<P>*Low risk of bias: any one of the following. The study protocol is available and all of the study's prespecified outcomes that are of interest in the review have been reported or the study protocol is not available but it is clear that the published report include all expected outcomes, including those that were prespecified</P>
<P>*High risk of bias: not all of the study's prespecified outcomes have been reported or one or more primary outcomes are reported using measurements, analysis methods or subsets of data that were not prespecified; or one or more reported primary outcomes were not prespecified, unless clear justification for their reporting is provided, such as an unexpected adverse effect, or one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study</P>
<P>*Unclear: there is insufficient information to permit judgement of "Low risk" or "High risk"</P>
<P>For each domain, two authors independently made the judgment of risk of bias in accordance with the following classification: Low risk of bias; High risk of bias; Unclear.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment effect measures had to be computed by means of relative risks (dichotomous data), hazard ratios, and standardised mean differences (continuous data). A narrative description of results was reported in the first-line chemotherapy studies. In the second-line chemotherapy studies it was possible to obtain an overall effect measure of two studies. The third study was reported in a narrative. The statistical analysis was done in line with the recommendations of The Cochrane Collaboration using RevMan 5.2. We pooled the study specific hazard ratio estimates and their standard errors to obtain an overall hazard ratio and its 95% confident interval. We used as the method of meta-analysis the inverse variance with the random-effects model of Der Simonian and Laird to calculate the effect size, because of the clinical and methodological heterogeneity of the studies. Heterogeneity in the effect estimates was quantified with the I<SUP>2</SUP> statistic, which indicates the proportion of the total variation in the estimates that is caused by variation between studies not by chance. We considered I<SUP>2</SUP> &lt; 25% as representing low heterogeneity and I<SUP>2</SUP> &gt; 75% as representing high heterogeneity.</P>
<P>Missing data were dealt with by analysing only the available data and not if the trial authors did not provide them. The potential impact of missing data on the findings of the review were addressed in the discussion section.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis in all the included trials was the patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>To obtain data not available in the included studies, we attempted to contact the principal study investigators.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>In terms of clinical heterogeneity, we explored any kind of variability among studies. We assessed baseline group imbalance as well as other sources of clinical heterogeneity such as different diagnostic methods among the studies and groups, adverse effects, differences in dose of drug, length of follow-up, and characteristics of participants. We explored heterogeneity in the meta-analysis by comparing studies in terms of methodological factors such as concealment of allocation, the definition and measurement of outcomes, as well as in relation to clinical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>We took into account the following:</P>
<UL>
<LI>publication bias, by contacting pharmaceutical companies for non-published studies; duplicate publication; reporting of outcomes; no language restrictions for inclusion of trials;</LI>
<LI>the influence of external funding and commercial interests;</LI>
<LI>a search of multiple database sources, and consulting trials registries.</LI>
</UL>
<P>Since very few studies were included, we did not explore the use of funnel plots.</P>
</BIAS_ASSESSMENT>
<SUBGROUP_ANALYSIS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses were to be done for subsets of participants (gender, age) or for subsets of studies (low risk versus high risk of bias) as a means of evaluating heterogeneous results, if there were a substantial number of studies.</P>
<P>As it was not possible to perform any subgroup analysis in this review, we reported either differences in study and patient characteristics, the way in which outcomes were defined or measured, protocol requirements, the length of follow-up, or differential losses to follow-up. That is, clinical or methodology heterogeneity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>No sensitivity analysis was performed due to the small number of included studies. References to better quality studies were described.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-19 19:12:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-11-19 18:51:43 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-11-19 18:49:30 +0100" MODIFIED_BY="José Angel Exposito">
<P>From the literature search we obtained 16,282 references, 12,328 from MEDLINE and CENTRAL and 3954 from EMBASE, after excluding duplicates. We identified 50 potentially eligible trials in the first update and another five in the second update (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Only five trials compared first or second-line chemotherapy versus placebo or BSC: two compared first-line chemotherapy versus supportive care or no active anticancer treatment (<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>) and the other three compared second-line chemotherapy at relapse or progression versus symptomatic treatment or BSC (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>). In the search for the second update we found the Ciuleanu trial; two reports of quality of life in relation to <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>, one was a repetition of the same results of the study so it was excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>), the other study (<LINK REF="STD-O_x0027_Brien-2007a" TYPE="STUDY">O'Brien 2007a</LINK>) offered complementary information about quality of life and was included; another study, which was a retrospective report, was excluded. The Ciuleanu study was in abstract form and we consulted the Poniard website of the study (www.prnewswire.com/news-releases/poniard-announces-final-data-from-phase-3-spear-trial-of-picoplatin-in-small-cell-lung-cancer-95693244.html) for more complete information. We did not identify any studies of first-line chemotherapy versus BSC after 2003, when the original review took place. We received no response from the pharmaceutical companies that we contacted for information about any possible non-published studies except for Lilly and Astra Zeneca saying that they had no unpublished studies corresponding to our review. Contact was established with the principal author of the Ciuleanu 2010 study but he was not able to reply to our questions due to the fact that the study's data are the property of Poniard Pharmaceuticals; the company did not reply to his questions either.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-11-19 18:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>This review focused on the two trials by Kokron (<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>), identified in the original review of 2003, and on the three trials by Spiro, O&#8217;Brien, and Ciuleanu (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>), the only ones that fulfilled the inclusion criteria.</P>
<SUBSECTION>
<HEADING LEVEL="5">First-line chemotherapy versus best supportive care (BSC)</HEADING>
<P>Two studies included a total of 88 patients. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for further details.</P>
<P>
<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK> included 34 patients (33 evaluable) selected from 1972 to 1974 with the objective of comparing ifosfamide with supportive care.</P>
<P>
<LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK> was published in 1982 and included 54 eligible patients (41 of them with extensive disease, 32 evaluable) selected between 1975 and 1979. The objective of this study was to compare ifosfamide versus ifosfamide plus chloroethyl-cyclohexyl-nitrosourea (CCNU) versus no active anticancer treatment. Both studies were carried out at the City Hospital Lainz, Vienna.</P>
<P>The inclusion criteria for the trials were: male patients; age under 70 years; inoperable small cell carcinoma of the bronchus with histological or cytological verification of tumour, or both; no previous tumour therapy; no large total tumour mass; no detected brain metastasis at the start of therapy; no chronic disease (cardiac, hepatocirrhosis, renal insufficiency, insulin dependent diabetes, or impediment in the region of the urinary tract)<B> </B>and good general condition (able to work) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Second-line chemotherapy at relapse versus best supportive care (BSC)</HEADING>
<P>Three studies included a total of 932 patients. See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for more information.</P>
<P>
<LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK> included 616 patients (610 evaluable), 414 of them with advanced SCLC, recruited from 1982 to 1985 at various institutions in the United Kingdom. Second-line chemotherapy or symptomatic treatment was administered to 390 patients in progression (170 evaluable in active treatment).</P>
<P>
<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> included 141 patients (141 evaluable) recruited from 2000 to 2004 at 40 centres in Europe, Canada, and Russia.</P>
<P>
<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK> included 401 patients (321 evaluable) with refractory disease or SCLC in progression within six months of first-line chemotherapy, recruited from international multi-centre sites.</P>
<P>The inclusion criteria for the trials were: both sexes; age under 75 years (<LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>) or &#8805; 18 years (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>); median age 58 years (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>); SCLC diagnosed by histology or by cytology; previous chemotherapy; no symptomatic brain metastases (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>); no severe co-morbidities; no previous treatment with topotecan (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>); any performance status (<LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>) or between 0 and 2 (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>).</P>
<P>The primary endpoint in the five trials was overall survival. Secondary endpoints were response rate, quality of life, and safety.</P>
<P>Supplementary data from the Kokron studies were supplied by the author. We were unable to establish contact with the rest of authors.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 48 studies were excluded. These studies did not include a comparison of a chemotherapeutic agent with placebo or BSC, were phase II trials without a control group, or they compared second-line chemotherapy in a complete or partial response with observation (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-19 18:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>See the 'Risk of bias' tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="José Angel Exposito">
<P>The allocation strategy was considered unclear for the five trials (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-O_x0027_Brien-2007a" TYPE="STUDY">O'Brien 2007a</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>), while allocation concealment was judged adequate for one trial (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-O_x0027_Brien-2007a" TYPE="STUDY">O'Brien 2007a</LINK>) and unclear for the other four trials (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>). Although we actively contacted the authors requesting information about their trials, we received no replies.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-11-19 18:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding was not used in four of the five trials but the main outcome of survival is not likely to be influenced by lack of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="José Angel Exposito">
<P>Losses to follow-up and their reasons were reported in only one trial (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-O_x0027_Brien-2007a" TYPE="STUDY">O'Brien 2007a</LINK>). Attrition data seemed to be different between groups.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant outcomes for this review were reported in only one trial (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-O_x0027_Brien-2007a" TYPE="STUDY">O'Brien 2007a</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>) were considered to be affected by other sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-11-19 19:12:14 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">A) First-line chemotherapy versus best supportive care (BSC)</HEADING>
<P>The results were based on a total of 65 assessed patients with advanced disease who were included in two studies (<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>). Information about the baseline data of the patients in the two arms and a calculation of sample size were not found in the Kokron reports. The published studies of Kokron did not provide sufficient details about the analyses performed, although survival curves were used to compare survival between groups in both studies. Information that was later provided by the author referred to ANOVA to compare the three groups in the second study (<LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>).</P>
<P>Because it was not possible to obtain data suitable for a combined analysis, the results were described separately for each study according to the data provided by the author. Results for each study are presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="6">Survival</HEADING>
<UL>
<LI>
<I>Mean survival </I>
</LI>
</UL>
<P> In <LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>, treatment with ifosfamide gave a mean survival time that was 79 days longer than in the supportive care group. Available data did not allow calculation of the confidence interval.</P>
<P>In <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>, the data for all patients (limited and extensive disease) showed a significant difference (P = 0.01) in the mean survival time between the no active anticancer treatment and the ifosfamide groups and between the no active anticancer treatment and the ifosfamide + CCNU groups. No significant differences were found between the ifosfamide and ifosfamide + CCNU groups. For patients with extensive disease, where only the mean survival time was reported by the author, the mean survival time was 78 days longer (P = 0.01) for the ifosfamide group and 66 days longer (P = 0.01) for the ifosfamide + CCNU group in comparison with the no active anticancer treatment group. In addition, in the ifosfamide group the mean survival time was 12 days longer (P = 0.05) than in the group receiving ifosfamide + CCNU. The quality of the evidence was very low for this outcome. (See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tumour response</HEADING>
<P>No patients in <LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK> showed a complete response. However, eight patients (47%) in the ifosfamide group showed a partial response at 5.6 months versus no patients in the control group. In <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK> only one patient in the ifosfamide treatment group had a complete tumour response. Nine patients in the ifosfamide group and seven in the ifosfamide + CCNU group showed a partial tumour response. These data referred to all patients (limited and extensive disease) as the author did not report data specifically for patients with extensive disease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Toxicity</HEADING>
<P>In <LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK> six patients (94.1%) treated with ifosfamide had haematological toxicity (its type was not reported) compared with none in the supportive care group. In <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>, data on toxicity referred to all patients (limited and extensive disease), where no cases of toxicity were recorded for the no active anticancer treatment group (very low-quality evidence).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Quality of life</HEADING>
<P>No validated instruments were used to assess quality of life in the Kokron studies (<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>). Patients&#8217; levels of activity were assessed (<LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>) using a simple scale: 0: no symptoms, 1: subjective symptoms only, 2: objective signs of illness but able to work, 3: needing care, 4: bedridden, 5: confused and disorientated. No information or reference was given concerning its validation. Data based on this scale were reported only for the beginning of treatment (for all patients together, limited and extensive disease) when 34 had an activity level of 1 and 18 were level 2. The data also showed that 61% of patients in the first group, 80% in the second, and 53% in the third presented a subjective feeling of disease with a score of 1 on the scale. No specific information was mentioned for patients with extensive disease and no measurement of this scale was reported at the end of the study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">B) Second-line chemotherapy versus best supportive care (BSC) at relapse or progression</HEADING>
<P>The results of this comparison were based on a total of 932 patients with advanced disease who were included in three studies (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>). All patients in progression or relapse were considered as having extensive disease in this review. Information about the baseline data of patients in the two arms and a calculation of sample size were described in <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>.</P>
<P>In <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>, randomisation took place at diagnosis not relapse and patient characteristics were described at presentation with either limited or extensive disease. O'Brien provided baseline characteristics of the patients but Ciuleanu did not.</P>
<P>Patients in <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK> were allocated to one of two groups: 192 (59 women) to the methotrexate-doxorubicin group and 198 (63 women) to the symptomatic treatment group. Patients in <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> were allocated to one of two groups: 71 (19 women) to the topotecan group and 70 (19 women) to the BSC group. Patients in the <LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK> study were allocated to one of two groups: 268 picoplatin, 133 BSC. Results for each study are presented in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> and in the 'Data analysis' section.</P>
<SUBSECTION>
<HEADING LEVEL="6">Survival</HEADING>
<UL>
<LI>
<I>Median survival</I>
</LI>
</UL>
<P>In <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>, survival data were provided in accordance with the first-line chemotherapy group allocation: treatment with methotrexate-doxorubicin at relapse gave a median survival time of 63 days longer than in the symptomatic treatment group (P &lt; 0.001) for patients allocated to receive four cycles of first-line chemotherapy, and 21 days longer (P = 0.160) for patients allocated to receive eight cycles of first-line chemotherapy. Confidence intervals were not reported. No survival comparisons between the symptomatic group versus the methotrexate group were provided.</P>
<P>In <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>, treatment with topotecan at relapse gave a median survival time 84 days longer than in the BSC group (log-rank P = 0.01). The hazard ratio for overall survival, adjusted for the stratification factors of sex, performance status 0/1 or 2, treatment-free interval &#8804; 60 days or &gt; 60 days, presence of liver metastases, was 0.61 (95% CI 0.43 to 0.87).</P>
<P>In all subgroup analyses in the <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> study (treatment-free interval &#8804; 60 days after first-line chemotherapy, performance status 2, female, liver metastasis) (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) the survival differences were maintained.</P>
<P>In <LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>, treatment with picoplatin in refractory patients or for patients in progression gave a median survival time six days longer than in the BSC group (HR 0.82, 95% CI 0.65 to 1.03, P = 0.0895). The time to progression was significant longer (32 days) in the picoplatin group in comparison with the BSC group, and the median progression-free survival was also significant longer (by 17 days) in the picoplatin group. Patients of both groups received second-line chemotherapy post-study, 27.6% in the picoplatin arm and 40.6% in the BSC arm (P = 0.012).</P>
<P>In the first subgroup analysis of patients who did not receive second-line chemotherapy post-study in either arm (picoplatin or BSC), and in the second subgroup analysis of patients refractory or relapsed within 45 days of first-line chemotherapy, a significant longer survival time was observed in the picoplatin group compared to the BSC group (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>The overall survival measured by means of the combined hazard ratio for topotecan plus picoplatin was 0.73 (95% CI 0.55 to 0.96, P = 0.03; low-quality evidence), with medium heterogeneity (47%), favouring second-line chemotherapy over BSC (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<UL>
<LI>
<I>Survival at six months</I>
</LI>
</UL>
<P>Data were extracted from the survival curves and in accordance with the previous chemotherapy received: <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK> symptomatic group previously four cycles 20%; previously eight cycles 22%; in the methotrexate-doxorubicin group previously four cycles 37%, previously eight cycles 32%.</P>
<P>Six-month survival rates were 26% in the BSC group and 49% in the topotecan group (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>). No data were provided in the picoplatin study (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>).</P>
<UL>
<LI>
<I>Survival at one year</I>
</LI>
</UL>
<P>Data were extracted from the survival curves and in accordance with previous chemotherapy received: <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK> symptomatic group previously four cycles 4%, previously eight cycles 2%; in the methotrexate-doxorubicin group previously four cycles 6%, previously eight cycles 5%.</P>
<P>One-year survival rates (extrapolated from the survival graphs) were 13% in the BSC group and 19% in the topotecan group (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>). No data were provided in the picoplatin study (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>).</P>
<UL>
<LI>
<I>Survival at two years</I>
</LI>
</UL>
<P>Two-year survival in patients with extensive disease at presentation, for both groups in <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>, were shown according to first-line chemotherapy allocation: 2% to 2.7% for the symptomatic group allocated to four and eight cycles respectively, and 1.1% to 1% for the methotrexate-doxorubicin group allocated to four and eight cycles, respectively. In <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> the two-year survival rates (extrapolated from the survival graphs) were 3% and 9% in the BSC and topotecan groups, respectively. No data were provided in the picoplatin study (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tumour response</HEADING>
<P>In <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>, in the methotrexate-doxorubicin group the partial or complete response was 22.3%; in <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> in the topotecan group there was no complete response and 7% showed a partial response; in <LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK> no data were provided for picoplatin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Toxicity</HEADING>
<P>No data were provided for the methotrexate-doxorubicin group (<LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>). Topotecan showed more toxicity than BSC (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>), with 6% toxic deaths in <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>. In the <LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK> study picoplatin showed more toxicity than BSC but with no deaths due to haematological toxicity (moderate-quality evidence).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Quality of life</HEADING>
<P>Quality of life was not measured for patients receiving methotrexate-doxorubicin chemotherapy in <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK> or for patients receiving picoplatin at relapse in <LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>.</P>
<P>
<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> used two questionnaires: the Patient Self Assessment (PSA) questionnaire, which resembles the Lung Cancer Symptom Scale, evaluating the degree to which patients experienced nine common symptoms on a Likert scale for severity (from 1, not at all, to 4, very much); and the EuroQol-5 Dimensions Health questionnaire (EQ-5D), consisting of the five health status dimensions mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The questionnaire has a rating scale from 1 (no problem) to 3 (an extreme problem), and a visual analogue scale ranking from 0 (worst imaginable health state) to 100 (best imaginable health state). Patients in both arms were evaluated before each course of second-line chemotherapy, or at each visit in the BSC arm. Not all patients completed the pre-specified questionnaires at the different visits.</P>
<P>The difference in rate of deterioration in the score at three-month intervals in the EQ-5D questionnaire was significantly lower in the topotecan group (0.15, 95% CI 0.05 to 0.25). The PSA questionnaire, conducted in 61 (86%) patients in the topotecan group and 48 (69%) in the BSC group, gave significant risk ratios for shortness of breath (RR 2.18, 95% CI 1.09 to 4.38), interference with sleep (RR 2.16, 95% CI 1.15 to 4.06) and fatigue (RR 2.29, 95% CI 1.25 to 4.19) (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>Patients with a lower functional status based on their Eastern Cooperative Oncology Group (ECOG) performance status (<LINK REF="STD-O_x0027_Brien-2007a" TYPE="STUDY">O'Brien 2007a</LINK>) reported more severe symptoms in the PSA questionnaire: mean score 12.31 for ECOG 0, 16.37 for ECOG 1, and 17.58 for ECOG 2 (P = 0.0002). Mean changes from baseline in the questionnaire score showed an association between tumour response and symptom control (P = 0.0016). Patients with a partial response (n = 5) had a baseline score of 15.07, while the mean score on treatment reduced to 12.64 representing a change from baseline of -2.43, or 16.12% improvement in symptoms. Patients with stable disease (n = 31) did not change their score between baseline and on treatment (15.33 versus 15.35) (low-quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-21 19:22:15 +0100" MODIFIED_BY="[Empty name]">
<P>The present study involved a comprehensive search of electronic databases and contact with authors and companies in order to identify trials that evaluated the efficacy of first-line and second-line chemotherapy at relapse as compared to best supportive care (BSC) or no active anticancer treatment.</P>
<SUMMARY_OF_RESULTS MODIFIED="2013-11-19 19:14:00 +0100" MODIFIED_BY="[Empty name]">
<P>Only the two studies by Kokron (<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>) met the inclusion criteria for the review of first-line chemotherapy compared with supportive care. These studies showed that for patients with extensive disease, ifosfamide gives an increased survival benefit (around 80 additional days) over supportive treatment but this benefit is not increased by the addition of CCNU. A partial tumour response of 47% was shown in the group on active therapy in the first study. Adverse effects were present in the chemotherapy group.</P>
<P>The results of this review in relation to second-line chemotherapy on relapse or at progression showed an increased survival benefit of between 63 days for patients receiving methotrexate-doxorubicin and 84 days for patients receiving topotecan over supportive treatment. No survival benefit was shown with picoplatin over BSC. According to <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>, the increase in survival after progression was significant in those patients who had previously received four cycles of first-line chemotherapy. The pooled analysis of topotecan and picoplatin gave an HR of 0.73 (95% CI 0.55 to 0.96) and significant improvement in overall survival. <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> reported that the increase in survival was preserved in women, the subgroup of patients with a treatment-free interval &#8804; 60 days, patients with a performance status of 2, and in patients with liver metastases. This survival benefit was accompanied by an improvement in the quality of life, with a difference in the rate of deterioration in EQ-5D questionnaire score at three monthly intervals significantly in favour of the topotecan group, together with an improvement in shortness of breath, interference with sleep, and fatigue in the PSA questionnaire. Tumour response (partial or complete) in the methotrexate-doxorubicin group was 22.3%. Five patients (7%, 95% CI 2.33 to 15.67) showed a partial response in the topotecan group without any complete responses reported.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-11-19 19:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence that is available on the effectiveness and toxicity of first-line chemotherapy for patients with extensive SCLC comes from two studies that compared ifosfamide and ifosfamide + CCNU versus supportive treatment (<LINK REF="STD-Kokron-1977b" TYPE="STUDY">Kokron 1977b</LINK>; <LINK REF="STD-Kokron-1982" TYPE="STUDY">Kokron 1982</LINK>). It remains unclear whether the results would be the same in women, patients with poor performance status, and in patients older than 70 years. Toxic deaths due to chemotherapy as well as the balance between quality of life and life expectancy remain unclear. At the time the studies were conducted no validated instruments for measuring quality of life were available. Such instruments were first developed in the 1980s, mainly with the objective of measuring self-perceived health in patients when the efficacy of a treatment was being evaluated (<LINK REF="REF-Lacombe-1997" TYPE="REFERENCE">Lacombe 1997</LINK>).</P>
<P>Despite the methodological limitations of these trials, carried out more than 25 years ago, they seem to have provided some evidence to support Green's hypothesis (<LINK REF="STD-Green-1969" TYPE="STUDY">Green 1969</LINK>) that first-line chemotherapy treatment for patients with advanced SCLC produces benefits in terms of more prolonged survival. Although a large number of clinical trials comparing different regimens have been conducted in advanced SCLC, to date no consistent findings have indicated what is the most effective combination. Platinum-based combination chemotherapy regimens have increased complete response rates with no significant benefit in survival when compared to non-platinum chemotherapy regimens (<LINK REF="REF-Amarasena-2009" TYPE="REFERENCE">Amarasena 2009</LINK>), and at present are the standard first line treatment for patients with SCLC.</P>
<P>The evidence available on the effectiveness of second-line chemotherapy at relapse or progression in patients with extensive SCLC comes from three studies that compared methotrexate-doxorubicin, topotecan, and picoplatin versus symptomatic treatment or BSC (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>; <LINK REF="STD-Spiro-1989" TYPE="STUDY">Spiro 1989</LINK>). It remains unclear whether the results would be the same in females, patients with treatment-free interval &#8804; 60 days after first-line chemotherapy, and in patients with poor performance status. The <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> study showed an improvement in survival in these subgroups and no subgroup-treatment effect interaction was reported. However, despite the fact that the trial was powered to determine the overall effect of treatment, virtually all subgroup analyses were underpowered. If a genuine subgroup-treatment effect interaction exists, the chance of a false negative result with a statistical test of interaction will be greater than the 5% false positive rate in a trial in which no true interaction exists (<LINK REF="REF-Rothwell-2005" TYPE="REFERENCE">Rothwell 2005</LINK>). Therefore, interpretation of the risks and benefits of topotecan in the subgroups should be done cautiously, and the findings need validation by replication of the data.</P>
<P>The relationship between the first-line chemotherapy received and the effect of second-line chemotherapy remains unclear. The most commonly received first-line chemotherapeutic agents in <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> and <LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK> were cisplatin or carboplatin and etoposide, consistent with current guidelines. It has been suggested that the clinical benefit of re-treatment correlates with the type of first-line chemotherapy and treatment characteristics at the time of relapse (treatment-free period), a presumption that is difficult to clarify in this study given the homogeneity of the type of first-line chemotherapy administered to patients.</P>
<P>Although treatment with picoplatin showed an improvement in the median time to progression and in the median progression-free survival, both are surrogates outcomes for the final outcome or overall survival. A recent review (<LINK REF="REF-Ciani-2013" TYPE="REFERENCE">Ciani 2013</LINK>) showed that, on average, trials using surrogate outcomes reported treatment effects that were 28% to 48% higher than trials using final relevant outcomes for patients. Surrogate trials were twice as likely to report positive treatment effects compared with the final outcome trials, and the findings were not explained by differences in risk of bias or other trial characteristics.</P>
<P>The quality of life of patients receiving second-line chemotherapy remains unclear. In this review only the topotecan study (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>) addressed this question, with an improvement in shortness of breath, quality of sleep, and fatigue.</P>
<P>In summary, the trials included in the review are clinically diverse and few; one of them has not been published in a peer-reviewed journal (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>), the survival benefit is limited, a few days, and the adverse effects are present in considerable proportions. Therefore, the evidence on the benefits of second-line chemotherapy in patients with extensive SCLC at relapse or progression is scarce, making it difficult to generate recommendations to clinicians and patients.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-11-21 19:22:15 +0100" MODIFIED_BY="José Angel Exposito">
<P>The quality of the evidence available for all comparisons was moderate to very low, mainly because there were only two studies for first-line chemotherapy and three for second-line chemotherapy, with small sample sizes and significant risk of bias. Selection bias was considered unclear in all studies except <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>. Performance bias in relation to survival seemed to be at low risk of bias in all studies, although at unclear risk in relation to toxicity and quality of life. Detection bias in relation to survival was considered to be at low risk in all studies but unclear in relation to tumour response, toxicity and quality of life. Attrition bias in relation to survival was considered to be at low risk in <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK> and unclear in the rest of studies. In relation to tumour response, toxicity and quality of life attrition bias was at a mix of low, unclear and high risk bias. Selective reporting was considered to have unclear bias in all studies except <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>, and four studies were considered to be affected by other bias.</P>
<P>For first-line chemotherapy the quality of the evidence for the overall survival and adverse events was very low. No evidence was found for quality of life. For second-line chemotherapy the quality of the evidence for the overall survival and quality of life was low, and moderate for toxic deaths and adverse effects.</P>
<P>In relation to other bias, the lack of information on the baseline characteristics of the treatment groups in the Kokron studies, Spiro, and Ciuleanu means that the presence of uncontrolled confounding variables cannot be excluded. Moreover, the small number of patients in each comparison group in the Kokron studies may have led to an overestimation of the effects, as has been described in other circumstances (<LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>). The ANOVA statistical analysis in the Kokron studies is inadequate to compare mean survival between groups. As well, the Kaplan-Meier method was inadequate and the statistical analysis should have included a Mantel-Haenszel analysis to compare treatment groups (<LINK REF="REF-Kleinbaum-1996" TYPE="REFERENCE">Kleinbaum 1996</LINK>). Two trials (<LINK REF="STD-Ciuleanu-2010" TYPE="STUDY">Ciuleanu 2010</LINK>; <LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>) were designed by the sponsors Poniard Pharmaceuticals and Glaxo-Smith-Kline, respectively, who held and analysed the data. Eight of the 10 authors in the O'Brien study disclosed potential conflicts of interest, all of them with the same sponsor, and the trial favoured the drug. A recent systematic review (<LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>) on the relationship between pharmaceutical industry sponsorship and research outcomes found that clinical trails sponsored by the pharmaceutical companies are significantly more likely than non-commercially funded studies to report favourable efficacy and safety results and conclusions. The findings were consistent across a wide range of disease states and drugs, regardless of the type of research being assessed. The review did not find a difference in risk of bias of drugs and device trials sponsored by industry compared with non-industry sponsored trials. However, industry sponsored trials more often had low risk of bias from blinding. Although the research methods of trials sponsored by drug companies are reported to be at least as good as or, in many cases, even better than those of non-industry funded research, this does not guarantee the absence of bias.</P>
<P>Except for the Kokron 1982 blinding was not used to evaluate the results so measurement bias for variables such as tumour response, toxicity, and quality of life cannot be excluded, although this is less important when survival is the outcome being measured (<LINK REF="REF-Day-2000" TYPE="REFERENCE">Day 2000</LINK>).<BR/>
</P>
<P>The attrition bias shown in the studies prevents a full intention-to-treat analysis being carried out (<LINK REF="REF-Dumville-2006" TYPE="REFERENCE">Dumville 2006</LINK>). No information on the cause of the missing data is reported, neither were there analytical methods to deal with data that are not missing at random (<LINK REF="REF-Bell-2013" TYPE="REFERENCE">Bell 2013</LINK>).</P>
<P>The major strength of the review is that it is a comprehensive analysis of all the studies undertaken on the subject. The major limitation is the scarce number of studies included, the unclear risk of bias in the first-line chemotherapy studies and the majority of second-line chemotherapy studies, except for only one study that was judged to be at low risk of bias in some aspects such as allocation concealment, performance and detection of survival, attrition and outcome reporting (<LINK REF="STD-O_x0027_Brien-2006" TYPE="STUDY">O'Brien 2006</LINK>). Given the paucity of available robust studies assessing the clinical effects of first-line chemotherapy and second-line chemotherapy at relapse or progression over BSC, the evidence is insufficient to judge the effectiveness and safety of chemotherapy for the treatment of extensive SCLC with the desired degree of precision.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>There was no language restriction in the search for trials and trial selection. Pharmaceutical companies were contacted for supplementary data on any non-published studies but no answer was received so publication bias could not be excluded. Conference abstracts were not searched. Given the few trials included in the review, no funnel plot could be drawn.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-11-11 16:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>We did not find any systematic review of first-line chemotherapy treatment in advanced SCLC to compare with the results of this review with. In spite of limited evidence concerning the benefits of first-line chemotherapy, many would now consider it unethical not to give chemotherapy to patients with advanced SCLC.</P>
<P>According to a few studies, it seems that patients with advanced disease and poor prognostic factors (brain metastases, low performance status, biochemical anomalies such as increased lactate dehydrogenase (LDH), alkaline phosphatase, and sodium anomalies) have a higher mortality during the first chemotherapy cycle as a consequence of toxicity (<LINK REF="REF-Bernhard-1996" TYPE="REFERENCE">Bernhard 1996</LINK>; <LINK REF="REF-Rawson-1990" TYPE="REFERENCE">Rawson 1990</LINK>; <LINK REF="REF-Souhami-1988" TYPE="REFERENCE">Souhami 1988</LINK>). None of the studies included in this review reported on the number of early deaths due to chemotherapy in patients with a poor prognosis. So the benefits of first-line chemotherapy in patients with poor prognosis remain unclear.</P>
<P>We did find four reviews of second-line chemotherapy in SCLC patients at relapse or progression to compare with the results of this review. The <LINK REF="REF-Seidenfeld-2006" TYPE="REFERENCE">Seidenfeld 2006</LINK> evidence report made reference to two studies included in this review with the same conclusions as in our review. <LINK REF="REF-Cheng-2007" TYPE="REFERENCE">Cheng 2007</LINK> included only the trial of O'Brien, with results similar to our review. <LINK REF="REF-Riemsma-2010" TYPE="REFERENCE">Riemsma 2010</LINK> included the O'Brien study and six other studies outside the inclusion criteria of this review, with similar findings to our review. <LINK REF="REF-Loveman-2010" TYPE="REFERENCE">Loveman 2010</LINK> developed an economic model to estimate the cost-effectiveness of oral or intravenous topotecan compared with BSC for patients with relapsed SCLC for whom re-treatment with the first-line regimen was not considered appropriate. It included the O'Brien study and four other trials outside the scope of this review. The cost difference gave an incremental cost-effectiveness ratio (ICER) of GBP 26,833 per QALY gained.</P>
<P>Benefit of first-line chemotherapy was shown in <LINK REF="REF-Sundstr_x00a2_m-2005" TYPE="REFERENCE">Sundstr¢m 2005</LINK>, an observational study that reported a survival benefit in favour of the chemotherapeutic group in comparison with supportive care (5.3 and 2.2 months, respectively).</P>
<P>However, no survival benefit was found for second-line chemotherapy in the retrospective <LINK REF="REF-Kim-2008" TYPE="REFERENCE">Kim 2008</LINK> study in which disease recurrence was more than three months compared with disease recurrence within three months without the chemotherapy.</P>
<P>The unclear benefit of second-line chemotherapy in women that was found in this review with topotecan has been remarked on by <LINK REF="REF-Weatley_x002d_Price-2010" TYPE="REFERENCE">Weatley-Price 2010</LINK> in a pooled analysis of chemotherapy trials, although at the same time the women experienced greater levels of grade 3/4 emesis.</P>
<P>The treatments in the studies of this review were administered intravenously and thus it was not possible to evaluate the benefit of oral chemotherapy over BSC. Yet oral administration is preferred by patients over intravenous therapies, including in the case of topotecan (<LINK REF="REF-Gralla-2004" TYPE="REFERENCE">Gralla 2004</LINK>).</P>
<P>The effectiveness of intense follow-up after a response in patients with SCLC treated with first-line chemotherapy has not been addressed in this review. However, an evaluation study (<LINK REF="REF-Sugiyama-2008" TYPE="REFERENCE">Sugiyama 2008</LINK>) reported that survival was significantly longer in an intense follow-up arm (MD 9 months, 95% CI 7 to 12 months) than in the non-intensive arm (4 months, 95% CI 2 to 7 months).</P>
<P>Given the poor prognosis of extensive SCLC and the report that 69% of patients with extensive lung cancer have inaccurate expectations about the benefits of chemotherapy that are not consistent with their life expectancy (<LINK REF="REF-Weeks-2012" TYPE="REFERENCE">Weeks 2012</LINK>), this misunderstanding could represent an obstacle in optimal end-of-life planning and care.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-11-21 18:45:54 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-11-21 18:45:54 +0100" MODIFIED_BY="[Empty name]">
<P>SCLC is an aggressive and fatal disease in the short term. Two small RCTs from the 1970s suggest that first-line chemotherapy treatment (based on ifosfamide) may provide a small survival benefit (less than three months) in comparison with supportive care or placebo infusion in patients with advanced SCLC, particularly those younger than 70 years with good performance status. The benefits remain unclear in older patients, women, and patients with poor performance status. However platinum-based combination chemotherapy regimens have been shown to increase complete response rates when compared to non-platinum chemotherapy regimens with no significant difference in survival, and so these are currently the standard first-line treatment for patients with SCLC.</P>
<P>Second-line chemotherapy (based on topotecan) at relapse or on progression could increase survival by a few weeks in patients with no symptomatic brain metastases and any performance status compared to best supportive care (BSC). Its benefits remains unclear in women, patients with a treatment-free interval &#8804;60 days after first-line chemotherapy and in patients with liver metastases.</P>
<P>Globally, the evidence on which these conclusions are based is very scarce and of uncertain or low quality, so it would be necessary to explain to patients the weak evidence for any benefit attributable to chemotherapy as well the poor prognosis of the disease in the short term, in a way that is understandable by them, in order to avoid inaccurate expectations.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-11-19 18:36:26 +0100" MODIFIED_BY="[Empty name]">
<P>Since chemotherapy with more modern agents is now established treatment for patients with SCLC, it is likely that a new study comparing active chemotherapy with BSC would be considered unethical. New studies comparing different drugs or combinations could be undertaken, with ifosfamide as the necessary comparator. The feasibility and ethics of conducting studies comparing active treatment with BSC in patients with poor prognosis (with poor performance status, women, or older people) could also be considered. This would allow the setting of more clear and explicit criteria to guide when to stop chemotherapy, with the objective of preserving quality of life.</P>
<P>In patients with SCLC that has relapsed or progressed, the uncertainty about the trade-offs between potential benefits (a gain of some weeks in survival), probable toxicity, and associated costs, coupled with the paucity and dubious quality of the available studies, would justify more trials comparing second-line chemotherapy versus BSC. These randomised clinical trials should be well-designed and large enough to allow assessment of the benefits in pre-specified subgroups such as women, older patients, people with low performance status, and previous response to first-line chemotherapy. These trials should also evaluate the effectiveness of follow-up schedules after first-line chemotherapy and include the use of validated instruments to measure quality of life. In addition, the information provided by the new, studies could be presented to patients and relatives in some objective way to enable them to make well-informed decisions on the potential risks and benefits of available therapeutic options.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>We would Iike to thank Dr Kokron for providing further information on his trials. We are grateful to Dr Elinor Thompson for helpful comments provided during the development of the initial review and to Marta Roque for her helpful comments provided in the analysis of the study data. Thanks to Desiree West (consumer of the Lung Cancer Group) for her comments on the review.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-02-11 09:13:53 +0100" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="José Ángel Expósito Losada">
<P>Marta Pelayo, Virginie Westeel, Marcela Cortés-Jofré undertook all the parts of this update, with the help of Xavier Bonfill who reviewed the update and gave the necessary feedback.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-02-09 21:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-21 19:20:38 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ciuleanu-2010" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ciuleanu 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciuleanu T, Samarzjia M, Demidchik Y, Beliakouski V, Rancic M, Bentsion DL, et al</AU>
<TI>Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy</TI>
<SO>Journal of Clinical Oncology (ASCO)</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>15 Suppl</NO>
<PG>7002</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokron-1977b" MODIFIED="2013-02-20 09:27:48 +0100" MODIFIED_BY="[Empty name]" NAME="Kokron 1977b" YEAR="1977">
<REFERENCE MODIFIED="2013-02-20 09:27:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokron O, Titscher R, Micksche M, Cerni C, Wrba H</AU>
<TI>Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl)</TI>
<SO>Osterreichische Kneipp Magazin</SO>
<YR>1977</YR>
<VL>15</VL>
<PG>103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokron-1982" MODIFIED="2013-02-20 09:29:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kokron 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-02-20 09:29:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokron O, Mickshe M, Titscher R, Wrba H</AU>
<TI>Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study</TI>
<SO>Onkologie</SO>
<YR>1982</YR>
<VL>56</VL>
<PG>56-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2006" MODIFIED="2013-02-20 09:30:50 +0100" MODIFIED_BY="José Angel Exposito" NAME="O'Brien 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-20 09:30:50 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al</AU>
<TI>Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>5441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2007a" MODIFIED="2013-04-07 20:58:39 +0200" MODIFIED_BY="[Empty name]" NAME="O'Brien 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-04-07 20:58:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brian ME, Duh MS, Chen L, Antras L, Neary M, Gralla RJ</AU>
<TI>An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1-224</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>8</NO>
<PG>S827</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiro-1989" MODIFIED="2013-02-20 09:32:16 +0100" MODIFIED_BY="José Angel Exposito" NAME="Spiro 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-02-20 09:32:16 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al</AU>
<TI>Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial</TI>
<SO>British Journal of Cancer</SO>
<YR>1989</YR>
<VL>59</VL>
<PG>578-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-AlIan-1984" MODIFIED="2013-02-20 09:52:24 +0100" MODIFIED_BY="[Empty name]" NAME="AlIan 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-02-20 09:52:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allan SG, Gregor A, Cornbleet MA, Leonard RC, Smyth JF, Grant IW, et al</AU>
<TI>Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1984</YR>
<VL>13</VL>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1993" MODIFIED="2013-02-20 09:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-02-20 09:54:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson FI, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L</AU>
<TI>A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1993</YR>
<VL>67</VL>
<PG>1385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ardizzoni-2002" MODIFIED="2013-02-20 09:56:24 +0100" MODIFIED_BY="José Angel Exposito" NAME="Ardizzoni 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-20 09:56:24 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka Mlodkowska FI, et al</AU>
<TI>Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group phase III trial-08923</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>3947-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beith-1996" MODIFIED="2013-02-20 09:57:41 +0100" MODIFIED_BY="[Empty name]" NAME="Beith 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-02-20 09:57:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA</AU>
<TI>Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung</TI>
<SO>European Journal of Cancer</SO>
<YR>1996</YR>
<VL>32A</VL>
<PG>438-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleehen-1989" MODIFIED="2013-02-20 09:59:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bleehen 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-02-20 09:59:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleehen NM, Fayers PM, Girling DJ, Stephens RJ</AU>
<TI>Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1989</YR>
<VL>59</VL>
<PG>584-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleehen-1993" MODIFIED="2013-02-20 10:01:06 +0100" MODIFIED_BY="José Angel Exposito" NAME="Bleehen 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-02-20 10:01:06 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleehen NM, Girling DJ, Machin D, Stephens RJ</AU>
<TI>A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party</TI>
<SO>British Journal of Cancer</SO>
<YR>1993</YR>
<VL>68</VL>
<PG>1157-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleehen-1996" MODIFIED="2013-02-20 10:02:26 +0100" MODIFIED_BY="[Empty name]" NAME="Bleehen 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-02-20 10:02:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleehen NM, Girling D, Hopwood P, Lallemand G, Machin D, Stephens RI, et al</AU>
<TI>Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<PG>406-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Candido-2002" MODIFIED="2013-02-20 10:04:44 +0100" MODIFIED_BY="[Empty name]" NAME="Candido 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-20 10:04:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Candido P, Cavallaro G, Piatti G, Bucchioni E</AU>
<TI>Results of a combined phase II study on small celI lung cancer</TI>
<SO>Giornale Italiano Delle Malattie del Torace</SO>
<YR>2002</YR>
<VL>56</VL>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen L, Antras L, Duh MS, Pickard S, Cella D, Neary M, et al</AU>
<TI>Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer?: D1-06</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>8</NO>
<PG>S391-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciuleanu-2002" MODIFIED="2013-02-20 10:06:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ciuleanu 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-02-20 10:06:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciuleanu TE, Curca R, Iancu D, Todor N, Cebotaru C, Fadulescu I, et al</AU>
<TI>First-Iine chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study</TI>
<SO>Journal of the Balkan Union of Oncology</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>43-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CuIlen-1986" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="CuIlen 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al</AU>
<TI>Maintenance chemotherapy for anaplastic small celI carcinoma of the bronchus: a randomised, controlled trial</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1986</YR>
<VL>17</VL>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EarI-1991" MODIFIED="2013-02-20 10:11:52 +0100" MODIFIED_BY="[Empty name]" NAME="EarI 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-02-20 10:11:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, Law CS, et al</AU>
<TI>A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial</TI>
<SO>British Journal of Cancer</SO>
<YR>1991</YR>
<VL>64</VL>
<PG>566-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eridani-1978" MODIFIED="2013-03-04 16:38:29 +0100" MODIFIED_BY="[Empty name]" NAME="Eridani 1978" YEAR="1978">
<REFERENCE MODIFIED="2013-03-04 16:38:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eridani S, Burdick L, Maggio L, Cunietti E, Periti M, Arosio A, et al</AU>
<TI>Combined chemotherapy for unresectable carcinoma of the lung: a randomised trial</TI>
<SO>International Journal of Clinical Pharmacology &amp; Biopharmacy</SO>
<YR>1978</YR>
<VL>16</VL>
<PG>182-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ettinger-1990" MODIFIED="2013-03-04 16:38:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ettinger 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-03-04 16:38:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC</AU>
<TI>A randomised comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>230-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garassino-2011" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Garassino 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Sglione S, et al</AU>
<TI>Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis</TI>
<SO>Lung Cancer</SO>
<YR>2011</YR>
<VL>72</VL>
<PG>378-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giaccone-1993" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Giaccone 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et al</AU>
<TI>Maintenance chemotherapy in small cell lung cancer: long-term results of a randomised trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>1230-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1969" MODIFIED="2013-02-20 10:19:32 +0100" MODIFIED_BY="José Angel Exposito" NAME="Green 1969" YEAR="1969">
<REFERENCE MODIFIED="2013-02-20 10:19:32 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green R, Humphrey E, Close H, Patno M</AU>
<TI>Alkylating Agents in Bronchogenic Carcinoma</TI>
<SO>American Journal of Medicine</SO>
<YR>1969</YR>
<VL>46</VL>
<PG>516-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GrideIIi-2002" MODIFIED="2013-03-04 16:39:53 +0100" MODIFIED_BY="[Empty name]" NAME="GrideIIi 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-04 16:39:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gridelli C, Rossi A, Barletta E, Panza N, Brancaccio L, Cioffi R, et al</AU>
<TI>Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multi-centre phase II study</TI>
<SO>Lung Cancer</SO>
<YR>2002</YR>
<VL>36</VL>
<PG>327-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hainsworth-2002" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Hainsworth 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hainsworth ID, Morrissey LH, Scullin DC Jr, Houston GA, Prasthofer EF, Gray JR, et al</AU>
<TI>Paclitaxel, carboplatin, and topotecan in the treatment of patients with small celI lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<PG>2426-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanna-2002" MODIFIED="2013-03-04 16:40:09 +0100" MODIFIED_BY="José Angel Exposito" NAME="Hanna 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-04 16:40:09 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanna NH, Sandler AB, Loehrer PJ, Ansari R, Jung SH, lane K, et al</AU>
<TI>Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomised study</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>95-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-1996" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="James 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW, et al</AU>
<TI>A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-ceIl lung cancer: a Cancer Research Campaign trial</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<PG>1563-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joss-1995" MODIFIED="2013-03-04 16:40:34 +0100" MODIFIED_BY="José Angel Exposito" NAME="Joss 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-03-04 16:40:34 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joss RA, Alberto P, Hurny C, Bacchi M, Leyvraz S, Thurlimann B, et al</AU>
<TI>Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomised phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)</TI>
<SO>Annals of Oncology</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokron-1974a" MODIFIED="2009-08-03 05:40:36 +0200" MODIFIED_BY="[Empty name]" NAME="Kokron 1974a" YEAR="1974">
<REFERENCE MODIFIED="2009-08-01 17:08:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokron O</AU>
<TI>[Die Behandlung des kleinzelligen metastasierenden Bronchuskarzinoms mit Ifosfamid. Ergebnisse einer prospectiven randomisierten Studie]</TI>
<SO>Österreichische Zeitschrift für Onkologie</SO>
<YR>1974</YR>
<VL>5-6</VL>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-03 05:40:36 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokron-1974b" MODIFIED="2013-03-04 16:41:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kokron 1974b" YEAR="1974">
<REFERENCE MODIFIED="2013-03-04 16:41:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokron O</AU>
<TI>Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomised study [Die Behandlung des kleinzelligen Bronchuskarzinoms]</TI>
<SO>Osterreichische Kneipp Magazin</SO>
<YR>1974</YR>
<VL>5-6</VL>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokron-1977a" MODIFIED="2009-08-01 16:40:17 +0200" MODIFIED_BY="[Empty name]" NAME="Kokron 1977a" YEAR="1977">
<REFERENCE MODIFIED="2009-08-01 16:40:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokron O</AU>
<TI>[Klinische Erfahrungen mit Holoxan beim kleinzelligen Bronchuskarzinom]</TI>
<SO>Österreichische Zeitschrift für Onkologie</SO>
<YR>1977</YR>
<VL>4</VL>
<PG>103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korfel-2002" MODIFIED="2013-03-04 16:41:37 +0100" MODIFIED_BY="[Empty name]" NAME="Korfel 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-04 16:41:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korfel A, Oehm C, von Pawel J, Keppler U, Deppermann M, Kaubitsch S, et al</AU>
<TI>Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole brain irradiation. A multi-centre phase II study</TI>
<SO>European Journal of Cancer</SO>
<YR>2002</YR>
<VL>38</VL>
<PG>1724-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lebeau-1992" MODIFIED="2013-03-04 16:41:53 +0100" MODIFIED_BY="José Angel Exposito" NAME="Lebeau 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-03-04 16:41:53 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebeau B, Chastang Cl, Allard P, Migueres J, Boita F, Fichet D, et al</AU>
<TI>Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomised clinical trial</TI>
<SO>European Respiratory Journal</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>286-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyss-2002" MODIFIED="2013-03-04 16:42:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lyss 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-04 16:42:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyss AP, Herndon lI JE, Lynch Jr TJ, Turrisi AT, Watson DM, Grethlein SJ, et al</AU>
<TI>Novel doublets in extensive-stage small-cell lung cancer: A randomised phase II study of topotecan plus cisplatin of paclitaxel (CALGB 9430)</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattson-1992" MODIFIED="2009-02-12 19:28:45 +0100" MODIFIED_BY="[Empty name]" NAME="Mattson 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-02-12 19:28:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattson K, Niiranen A, Pyrhönen S, Holsti LR, Holsti P, Kumpulainen E, et al</AU>
<TI>Natural interferon alfa as maintenance therapy for small cell lung cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1992</YR>
<VL>28A</VL>
<PG>1387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattson-1997" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" NAME="Mattson 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattson K, Niiranen A, Ruotsalainen T, Maasilta P, Halme M, Pyrhönen, et al</AU>
<TI>Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival</TI>
<SO>Journal of Interferon and Cytokine Research</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>103-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurer-1980" MODIFIED="2013-03-04 16:42:27 +0100" MODIFIED_BY="[Empty name]" NAME="Maurer 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-03-04 16:42:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, et al</AU>
<TI>A randomised combined modality trial in small cell carcinoma of the lung</TI>
<SO>Cancer</SO>
<YR>1980</YR>
<VL>45</VL>
<PG>30-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mok-2002" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Mok 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, et al</AU>
<TI>A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase 1 and II inhibitors) in the treatment of patients with small celI lung carcinoma</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>95</VL>
<PG>1511-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naka-2002" MODIFIED="2009-02-11 10:54:43 +0100" MODIFIED_BY="[Empty name]" NAME="Naka 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-11 10:54:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naka N, Kawahara M, Okishio K, Hosoe S, Ogawara M, Atagi S, et al</AU>
<TI>Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2002</YR>
<VL>37</VL>
<PG>319-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noda-2002" MODIFIED="2009-02-12 19:32:59 +0100" MODIFIED_BY="[Empty name]" NAME="Noda 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-12 19:32:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al</AU>
<TI>Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reck-1998" MODIFIED="2009-07-27 16:02:46 +0200" MODIFIED_BY="José Angel Exposito" NAME="Reck 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-27 16:02:46 +0200" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reck M, Haering B, Koschel G, Kaukel E, Von Pawel J, Gatzemeier U</AU>
<TI>Chemotherapy of advanced SCLC and NSCLC with Bendamustine - A phase II-study</TI>
<SO>Pneumologie</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>570-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1991" MODIFIED="2009-07-27 16:03:03 +0200" MODIFIED_BY="José Angel Exposito" NAME="Rosenthal 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-27 16:03:03 +0200" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal M, Kefford R, Raghavan D, Stuart-Harris R</AU>
<TI>Epirubicin: a phase II study in recurrent small-cell lung cancer</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1991</YR>
<VL>28</VL>
<PG>220-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiller-2001" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Schiller 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH</AU>
<TI>Topotecan versus observation alter cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>2114-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sculier-1996" MODIFIED="2009-02-12 19:38:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sculier 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-12 19:38:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, et al</AU>
<TI>Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>2337-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smit-1989" MODIFIED="2009-08-03 05:46:46 +0200" MODIFIED_BY="[Empty name]" NAME="Smit 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-08-03 05:46:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE</AU>
<TI>A phase II study of oral etoposide in elderly patients with small cell lung cancer</TI>
<SO>Thorax</SO>
<YR>1989</YR>
<VL>44</VL>
<PG>631-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souhami-1997" MODIFIED="2013-03-04 16:42:53 +0100" MODIFIED_BY="[Empty name]" NAME="Souhami 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-04 16:42:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al</AU>
<TI>Five-day oral etoposide treatment for advanced small-cell lung cancer: randomised comparison with intravenous chemotherapy</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>577-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundstrom-2002" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" NAME="Sundstrom 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al; Norwegian Lung Cancer Study Group</AU>
<TI>Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomised phase III trial with 5 years follow-up</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>4665-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tada-2002" MODIFIED="2009-07-27 16:03:47 +0200" MODIFIED_BY="José Angel Exposito" NAME="Tada 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-27 16:03:47 +0200" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tada A, Ueoka H, Kiura K, Tabata M, Takemoto M, Yamane H, et al</AU>
<TI>Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. [Japanese]</TI>
<SO>Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy]</SO>
<YR>2002</YR>
<VL>29</VL>
<PG>751-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thatcher-1996" MODIFIED="2013-03-04 16:43:21 +0100" MODIFIED_BY="José Angel Exposito" NAME="Thatcher 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-03-04 16:43:21 +0100" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thatcher N, Clark PI, Girling DJ, Hopwood P, Twiddy S, Stephens RJ, et al</AU>
<TI>Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multi-centre randomised trial</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<PG>563-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-2002" MODIFIED="2009-07-27 16:04:27 +0200" MODIFIED_BY="José Angel Exposito" NAME="Thomas 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-27 16:04:27 +0200" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD</AU>
<TI>A phase II study of CI-980 in previously untreated extensive small celI lung cancer: an Ohio State University phase II research consortium study</TI>
<SO>Cancer Investigation</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>192-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tjan_x002d_He_x00ed_jnen-2001" MODIFIED="2009-02-12 19:07:31 +0100" MODIFIED_BY="[Empty name]" NAME="Tjan-Heíjnen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-12 19:07:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tjan-Heijnen VCG, Postmus PE, Ardizzoni A, Manegold Ch, Burghouts J, Van-Meerbeeck J, et al</AU>
<TI>Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>1359-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanseenkiste-2001" MODIFIED="2013-03-04 16:44:37 +0100" MODIFIED_BY="[Empty name]" NAME="Vanseenkiste 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-03-04 16:44:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vansteenkiste J, Gatzemeier U, Manegold C, Hanauske A, Weynants P, Bosquée L, et al</AU>
<TI>Gemcitabine plus etoposide in chemo-naive extensive disease small-ceIl lung cancer: A multi-centre phase II study</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>835-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Pawel-1990" MODIFIED="2009-08-01 16:58:53 +0200" MODIFIED_BY="[Empty name]" NAME="von Pawel 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-08-01 16:58:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Pawel J, Wilke H, Vahee D, Dimbeck H, Schmohl HJ</AU>
<TI>Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease), [Article in German]</TI>
<SO>Pneumologie</SO>
<YR>1990</YR>
<VL>44</VL>
<PG>582-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2009-07-27 16:04:47 +0200" MODIFIED_BY="José Angel Exposito" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-27 16:04:47 +0200" MODIFIED_BY="José Angel Exposito" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Z, Hu Z, Lu X, Zeng L</AU>
<TI>Evaluation of topotecan combined with cisplatin in the treatment of small cell Iung cancer</TI>
<SO>Chinese Journal of Lung Cancer</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>354-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-02-28 17:58:20 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-21 19:20:38 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-21 19:20:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amarasena-2009" MODIFIED="2013-04-08 11:25:22 +0200" MODIFIED_BY="José Angel Exposito" NAME="Amarasena 2009" TYPE="COCHRANE_REVIEW">
<AU>Amarasena IU, Walters JAE, Wood-Baker R, Fong K</AU>
<TI>Platinum versus non-platinum chemotherapy regimens for small cell lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-03-04 16:45:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-04 16:45:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006849.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bell-2013" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Bell 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bell M, Kenward MG, Fairclough DL, Horton NJ</AU>
<TI>Differential dropout and bias in randomised controlled trials: when it matters and when it may not</TI>
<SO>BMJ</SO>
<YR>2013</YR>
<VL>346</VL>
<PG>e8668</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernhard-1996" MODIFIED="2009-07-27 16:05:05 +0200" MODIFIED_BY="José Angel Exposito" NAME="Bernhard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bernhard J, Hürny C, Bacchi M, Joss RA, Cavalli F, Senn HJ, et al</AU>
<TI>Initial prognostic factors in small-celI lung cancer patients predicting quality of life during chemotherapy</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>1660-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carney-2002" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Carney 2002" TYPE="JOURNAL_ARTICLE">
<AU>Carney D</AU>
<TI>Lung cancer - Time to move on from chemotherapy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>126-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheng-2007" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cheng S, Evans WK, Stys-Norman D, Shepherd FA; the Lung Cancer Disease Site Group of Cancer Care Ontario' Program in Evidence-based Care</AU>
<TI>Chemotherapy for relapse small cell lung cancer: a systematic review and practice guideline</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2007</YR>
<VL>2</VL>
<PG>348-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chutte-1999" MODIFIED="2013-02-19 18:50:59 +0100" MODIFIED_BY="[Empty name]" NAME="Chutte 1999" TYPE="JOURNAL_ARTICLE">
<AU>Chute J, Chen T, Feigal E, Simon R, Johnson B</AU>
<TI>Twenty years of phase III trials for patients with extensive-stage small celI lung cancer: perceptible progress</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>1794-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciani-2013" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ciani 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne J, et al</AU>
<TI>Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2013</YR>
<VL>346</VL>
<PG>457-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cort_x00e9_s_x002d_Jofr_x00e9_-2012" MODIFIED="2013-04-07 20:17:51 +0200" MODIFIED_BY="[Empty name]" NAME="Cortés-Jofré 2012" TYPE="COCHRANE_REVIEW">
<AU>Cortés Jofré M, Rueda JR, Corsini-Muñoz G, Fonseca-Cortés C, Carballoso M, Bonfill Cosp X</AU>
<TI>Drugs for preventing lung cancer in healthy people</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-03-21 17:29:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-21 17:29:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002141.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Day-2000" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" NAME="Day 2000" TYPE="JOURNAL_ARTICLE">
<AU>Day SJ, Altman DG</AU>
<TI>Blinding in clinical trials and other studies</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Vita-2000" MODIFIED="2013-02-19 17:59:48 +0100" MODIFIED_BY="José Angel Exposito" NAME="De Vita 2000" TYPE="BOOK">
<AU>De Vita V, Hellan S, Rosemberg S</AU>
<SO>Cancer: Principles &amp; Practice of Oncology</SO>
<YR>2000</YR>
<EN>Sixth</EN>
<PB>Lippincott</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Wet-1994" MODIFIED="2013-02-19 18:44:38 +0100" MODIFIED_BY="[Empty name]" NAME="De Wet 1994" TYPE="JOURNAL_ARTICLE">
<AU>De Wet M, Falkson G, Rapoport BL</AU>
<TI>Small cell Iung cancer: analysis of factors influencing the response to treatment and survival</TI>
<SO>Oncology</SO>
<YR>1994</YR>
<VL>51</VL>
<PG>523-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dumville-2006" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Dumville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dumville JC, Torgerson DJ, Hewitt CE</AU>
<TI>Reporting attrition in randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<PG>969-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Govindan-2006" MODIFIED="2009-07-27 16:06:45 +0200" MODIFIED_BY="José Angel Exposito" NAME="Govindan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al</AU>
<TI>Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>4539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gralla-2004" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Gralla 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gralla RJ</AU>
<TI>Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life</TI>
<SO>The Oncologist</SO>
<YR>2004</YR>
<VL>9 Suppl 6</VL>
<PG>14-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-02-19 19:14:22 +0100" MODIFIED_BY="José Angel Exposito" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011].</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollen-1994a" MODIFIED="2013-02-19 18:45:22 +0100" MODIFIED_BY="José Angel Exposito" NAME="Hollen 1994a" TYPE="JOURNAL_ARTICLE">
<AU>Hollen Pi, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, et al</AU>
<TI>Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>73</VL>
<PG>2087-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollen-1994b" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" NAME="Hollen 1994b" TYPE="JOURNAL_ARTICLE">
<AU>Hollen Pi, Gralla RJ, Kris MG, Cox C</AU>
<TI>Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1994</YR>
<VL>2</VL>
<PG>213-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ihde-1992" MODIFIED="2013-02-19 18:42:17 +0100" MODIFIED_BY="[Empty name]" NAME="Ihde 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ihde DC</AU>
<TI>Chemotherapy of lung cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>1434-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-2008" MODIFIED="2009-07-27 16:08:05 +0200" MODIFIED_BY="José Angel Exposito" NAME="Kim 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, et al</AU>
<TI>Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy</TI>
<SO>Cancer</SO>
<YR>2008</YR>
<VL>113</VL>
<PG>2518-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleinbaum-1996" MODIFIED="2009-07-27 16:08:26 +0200" MODIFIED_BY="José Angel Exposito" NAME="Kleinbaum 1996" TYPE="BOOK">
<AU>Kleinbaum DG</AU>
<SO>Survival analysis: A self-learning text</SO>
<YR>1996</YR>
<PB>New York: Springer-Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lacombe-1997" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" NAME="Lacombe 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lacombe D</AU>
<TI>Ethical Issues in cancer clinical trials: a European Perspective</TI>
<SO>European Journal of Cancer</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>184-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lassen-1998" MODIFIED="2009-07-27 16:08:43 +0200" MODIFIED_BY="José Angel Exposito" NAME="Lassen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lassen, Hirsch FR, Osterlind K, Bergman B, Dombernoswky P</AU>
<TI>Outcome of combination chemotherapy in extensive stage small-celI lung cancer: any treatment related progress?</TI>
<SO>Lung Cancer</SO>
<YR>1998</YR>
<VL>20</VL>
<PG>151-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loveman-2010" MODIFIED="2013-03-04 16:51:05 +0100" MODIFIED_BY="[Empty name]" NAME="Loveman 2010" TYPE="JOURNAL_ARTICLE">
<AU>Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A</AU>
<TI>The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation</TI>
<SO>Health Technological Assessment</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>19</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2013-11-21 19:20:30 +0100" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-11-21 19:18:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-21 19:18:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manser-2010" MODIFIED="2013-02-19 18:05:11 +0100" MODIFIED_BY="[Empty name]" NAME="Manser 2010" TYPE="COCHRANE_REVIEW">
<AU>Manser R, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D</AU>
<TI>Screening for lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-02-12 17:47:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-30 20:33:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001991.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1998" MODIFIED="2013-03-04 16:51:25 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Gevaghan D, Traver MR, Collins S, McQuay HJ</AU>
<TI>Size is everything. The impact of event rate variation on clinical trials and meta-analysis</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>208-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owonikoko-2007" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Owonikoko 2007" TYPE="JOURNAL_ARTICLE">
<AU>Owonikoko TK, Ragin CC, Belani ChP, Oton AB, Gooding WE, Taioli E, et al</AU>
<TI>Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results Database</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>5570-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oze-2009" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Oze 2009" TYPE="JOURNAL_ARTICLE">
<AU>Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al</AU>
<TI>Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results</TI>
<SO>PLOS ONE</SO>
<YR>2009</YR>
<VL>4</VL>
<PG>e7835</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rawson-1990" MODIFIED="2009-07-27 16:10:12 +0200" MODIFIED_BY="José Angel Exposito" NAME="Rawson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Rawson NS, Peto J</AU>
<TI>An overview of prognostic factors in small cell Lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research</TI>
<SO>British Journal of Cancer</SO>
<YR>1990</YR>
<VL>61</VL>
<PG>597-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riaz-2012" MODIFIED="2013-11-17 18:52:35 +0100" MODIFIED_BY="[Empty name]" NAME="Riaz 2012" TYPE="JOURNAL_ARTICLE">
<AU>Riaz PS, Lüchtenborg M, Coupland HV, Spicer J, Peake DM, Moller H</AU>
<TI>Trends in incidence of small cell lung cancer and all lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2012</YR>
<VL>75</VL>
<PG>280-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riemsma-2010" MODIFIED="2013-02-26 17:50:31 +0100" MODIFIED_BY="[Empty name]" NAME="Riemsma 2010" TYPE="JOURNAL_ARTICLE">
<AU>Riemsma R, Simons JP, Bashir Z, Gooch CL, kleijnen J</AU>
<TI>Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer</TI>
<SO>BMC Cancer</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>436-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothwell-2005" MODIFIED="2009-02-05 20:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Rothwell 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rothwell PM</AU>
<TI>Subgroup analysis in randomised controlled trials: importance, indications, and interpretation</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>176-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seidenfeld-2006" MODIFIED="2013-02-19 18:52:46 +0100" MODIFIED_BY="José Angel Exposito" NAME="Seidenfeld 2006" TYPE="OTHER">
<AU>Seidenfeld J, Samson  DJ, Bonnell CJ, Ziegler KM, Aronson N</AU>
<TI>Management of small cell lung cancer</TI>
<SO>Evidence Report/Technology Assessment No 143. AHRQ Publication No. 06-E016. Rockville, MD: Agency for Health Research and Quality</SO>
<YR>July 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Souhami-1988" MODIFIED="2009-07-27 16:10:53 +0200" MODIFIED_BY="José Angel Exposito" NAME="Souhami 1988" TYPE="JOURNAL_ARTICLE">
<AU>Souhami RL, Morittu L, Ash CM, EarI H, Geddes D, Harper PG, et al</AU>
<TI>Identification of patients at high risk of chemotherapy induced toxicity in SCLC</TI>
<SO>Antibiotics and Chemotherapy</SO>
<YR>1988</YR>
<VL>41</VL>
<PG>220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Souhami-1990" MODIFIED="2013-02-19 18:01:20 +0100" MODIFIED_BY="José Angel Exposito" NAME="Souhami 1990" TYPE="JOURNAL_ARTICLE">
<AU>Souhami RL, Law K</AU>
<TI>Longevity in small cell lung cancer. A report to the Lung Cancer SubCommitee of the United Kingdom Coordinating Commitee for Cancer Research</TI>
<SO>British Journal of Cancer</SO>
<YR>1990</YR>
<VL>61</VL>
<PG>584-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sugiyama-2008" MODIFIED="2009-07-27 16:11:34 +0200" MODIFIED_BY="José Angel Exposito" NAME="Sugiyama 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sugiyama T, Hirose T, Hosaka T, Kusumoto S, Nakashima M, Yamaoka T, et al</AU>
<TI>Effectiveness of intensive follow-up after response in patients with small cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2008</YR>
<VL>59</VL>
<PG>255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundstr_x00a2_m-2005" MODIFIED="2009-02-05 20:08:35 +0100" MODIFIED_BY="[Empty name]" NAME="Sundstr¢m 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sundstr¢m S, Bremnes RM, Kaasa S, Aaseb¢ U, Aamdal S</AU>
<TI>Second-line chemotherapy in recurrent small lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)</TI>
<SO>Lung Cancer</SO>
<YR>2005</YR>
<VL>48</VL>
<PG>251-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vrdoljak-2001" MODIFIED="2009-02-05 20:27:46 +0100" MODIFIED_BY="[Empty name]" NAME="Vrdoljak 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vrdoljak E, Mise K, Sapunar A, Rozga A, Marusic M</AU>
<TI>Staging in untreated patients with small cell Iung cancer</TI>
<SO>Neoplasma</SO>
<YR>2001</YR>
<VL>48</VL>
<PG>154-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weatley_x002d_Price-2010" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Weatley-Price 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, et al</AU>
<TI>The strength of female sex as prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit</TI>
<SO>Annals of Oncology</SO>
<YR>2010</YR>
<VL>21</VL>
<PG>232-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weeks-2012" MODIFIED="2013-03-04 16:55:19 +0100" MODIFIED_BY="[Empty name]" NAME="Weeks 2012" TYPE="JOURNAL_ARTICLE">
<AU>Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al</AU>
<TI>Patients' expectations about effects of chemotherapy for advanced cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>367</VL>
<PG>1616-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolf-2004" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="José Angel Exposito" NAME="Wolf 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wolf M, Tebbe S, Fink T</AU>
<TI>First-line chemotherapy in metastatic small-cell lung cancer (SCLC)</TI>
<SO>Lung Cancer</SO>
<YR>2004</YR>
<VL>Suppl 2</VL>
<PG>S223-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zelen-1973" MODIFIED="2009-07-27 16:11:51 +0200" MODIFIED_BY="José Angel Exposito" NAME="Zelen 1973" TYPE="JOURNAL_ARTICLE">
<AU>Zelen M</AU>
<TI>Keynote address on biostatistics and data retrieval</TI>
<SO>Cancer Chemotherapy Reports. Part 3</SO>
<YR>1973</YR>
<VL>4</VL>
<PG>31-42</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-04-08 10:49:47 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Agra-2003" MODIFIED="2013-04-08 10:49:16 +0200" MODIFIED_BY="[Empty name]" NAME="Agra 2003" TYPE="COCHRANE_REVIEW">
<AU>Agra Varela Y, Pelayo Alvarez M, Sacristan M, Sacristan Rodea A, Serra C, Bonfill Cosp X</AU>
<TI>Chemotherapy versus best supportive care for extensive small cell lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-04-08 10:49:16 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-08 10:49:16 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001990"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pelayo-2009" MODIFIED="2013-04-08 10:49:47 +0200" MODIFIED_BY="[Empty name]" NAME="Pelayo 2009" TYPE="COCHRANE_REVIEW">
<AU>Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y</AU>
<TI>Chemotherapy versus best supportive care for extensive small cell lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-04-08 10:49:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-08 10:49:47 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001990.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-11-21 18:47:26 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-11-21 18:47:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciuleanu-2010">
<CHAR_METHODS MODIFIED="2013-04-07 20:50:49 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-07 20:51:03 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised 401 patients, extensive disease refractory or in progression within 6 months of first-line chemotherapy</P>
<P>Evaluable 321, 84% male, median age 85 years, 88% Caucasian, 85% performance status 0-1, 15% performance status 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Arm A</B> (n=133): BSC</P>
<P>
<B>Arm B</B> (n=268): picoplatin IV 150 mg/m<SUP>2</SUP> every 3 weeks median cycles 3 (1-15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Median survival</P>
<P>Median survival in two subgroups (patients who did not received chemotherapy post-study, patients who were refractory or relapsed within 45 days of first-line chemotherapy)</P>
<P>Progression-free survival</P>
<P>Time to progression</P>
<P>Toxicity</P>
<P>Follow-up until death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Study published in abstract with complementary data on the Pharmaceutical website, without attrition data, tumour response, randomisation method. Sponsor: Poniard Pharmaceuticals</P>
<P>Uncertain/high risk of bias</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-19 18:54:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kokron-1977b">
<CHAR_METHODS MODIFIED="2009-02-06 19:43:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-06 19:54:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised 34 patients with extensive disease</P>
<P>Evaluable 33, (only male), 70 years or less (median age 64.5, 66, and 63 years), no prior therapy, no brain metastases, no relevant secondary diseases, good general condition (able to work)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-19 18:54:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Arm A</B> (n=17): supportive care.<BR/>
<B>Arm B</B> (n=17): Ifosfamide: 1500 iv day 1, followed by 1000 iv days 2 to 3, repeated on week 2 and 3, with initial dose of 1000 iv day 1. Repetition after 6 weeks. Two cycles<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-22 17:37:07 +0100" MODIFIED_BY="[Empty name]">
<P>Mean survival time<BR/>Tumour response (complete and partial response)<BR/>Toxicity</P>
<P>Follow-up: until death (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with extensive disease form a separate group</P>
<P>Bias with high probability</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-19 18:55:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kokron-1982">
<CHAR_METHODS MODIFIED="2009-02-06 19:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised 54 patients, 53 evaluable (32 extensive)<BR/>Extensive: Randomised 41, evaluable 32, (only male), 70 years or less (median age 62, 60.5, and 64 years), no prior therapy, no brain metastases, no relevant secondary diseases, good general condition (able to work)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-19 18:55:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Arm A </B>(n=8): no active anticancer treatment, Ringer solution 1000 ml + 1 g vitamin C iv 3 times wk, 6 weeks<BR/>
<B>Arm B</B> (n=12): Ifosfamide: 1500 iv day 1, followed by 1000 iv days 2 to 3, repeated on week 2 and 3, with initial dose of 1000 iv day 1<BR/>Repetition after 6 weeks<BR/>
<B>Arm C</B> (n=12): Ifosfamide + CCNU (cyclohexylnitrosourea), Ifosfamide as in Arm B + CCNU 60 mg/m<SUP>2</SUP> day 1<BR/>Repetition after 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Mean survival time<BR/>Tumour response (complete and partial response)<BR/>Toxicity</P>
<P>Follow-up: until death (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 19:22:32 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with extensive disease form a subgroup</P>
<P>Bias with high probability</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-2006">
<CHAR_METHODS MODIFIED="2009-02-06 20:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised 141 patients at relapse (38 female)</P>
<P>Evaluable 141, &gt; 18 years (median age = 58.6, 59.6 years), previous chemotherapy, no previous topotecan, no symptomatic brain metastases, no severe co-morbidities, performance status 0-2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Arm A </B>(n = 70): BSC</P>
<P>
<B>Arm B</B> (n = 71): topotecan in capsules containing the equivalent to 0.25 mg, dosed 2.3 mg/m<SUP>2</SUP> on days 1-5 every 21 days, at least 4 cycles + BSC                 </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-22 17:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Median survival time<BR/>Tumour response (complete and partial response)<BR/>Toxicity</P>
<P>Quality of life</P>
<P>Follow-up: until death  (within 30 days of random assignment: 9 patients (13%) in arm A, 10 (7%)  in arm B</P>
<P>Attrition data: 33 in arm A, 21 in arm B</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Compliance with topotecan was documented by returned capsule count (99% of patients took &#8805; 90% of capsules)</P>
<P>Sponsor: GlaxoSmithKline Pharmaceuticals</P>
<P>Low risk of bias</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-2007a">
<CHAR_METHODS MODIFIED="2013-04-07 20:53:04 +0200" MODIFIED_BY="[Empty name]">
<P>Report the results of quality of life of the O'Brien 2006 study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Same as O'Brien 2006</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Same as O'Brien 2006</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-07 20:53:16 +0200" MODIFIED_BY="[Empty name]">
<P>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-09 18:53:22 +0200" MODIFIED_BY="[Empty name]">
<P>It is the same study as O'Brien 2006 </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spiro-1989">
<CHAR_METHODS MODIFIED="2009-02-06 20:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Included 616 participants, 414 extensive. Randomised 390 patients on disease progression, (122 female). Evaluable 170 active treatment; no data in symptomatic; 75 years or less; (median age 62.5, 61.5 years); previous first-line chemotherapy, no severe co-morbidities, any performance status </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Arm A</B> (n= 198): symptomatic therapy  </P>
<P>
<B>Arm B</B> (n= 192): methotrexate 50 mg/m<SUP>2</SUP> iv plus doxorubicin 50 mg/m<SUP>2</SUP> iv, repeated every 3 weeks up to a maximum of 9 courses                              </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Median survival time<BR/>Tumour response (complete and partial response)<BR/>Toxicity</P>
<P>Follow-up: until death (no data)</P>
<P>Attrition data: 124 in arm B, no data in arm A </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-09 18:53:59 +0200" MODIFIED_BY="[Empty name]">
<P>High risk of bias</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-02-12 20:00:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AlIan-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 20:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of vinorelbine, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Ifosfamide-adryamicin in bolus plus oral etoposide versus continuous pump infusion of ifosfamide-adriamycin plus oral etoposide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-08 11:26:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ardizzoni-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-08 11:26:29 +0200" MODIFIED_BY="[Empty name]">
<P>Standard cyclophosphamide adriamycin etoposide versus intensified cyclophosphamide adriamycin etoposide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beith-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Induction chemoradiotherapy after randomisation to vincristine, doxorubicin,cyclophosphamide versus observation, in responding patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bleehen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Induction etoposide, cyclophosphamide, methotrexate, vincristine, after randomisation to further chemotherapy versus observation in partial or complete response</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bleehen-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Etoposide, cyclophosphamide, methotrexate, vincristine versus etoposide, ifosfamide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bleehen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Etoposide, cyclophosphamide, methotrexate, vincristine versus etoposide, vincristine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-27 12:10:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Candido-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-27 12:10:30 +0200" MODIFIED_BY="[Empty name]">
<P>Phase II study of ifosfamide, epirubicin, carboplatin, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-07 20:54:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-07 20:54:05 +0200" MODIFIED_BY="[Empty name]">
<P>Report the same quality of life results as O'Brien 2006, study included in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 23:18:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciuleanu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 23:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of teniposide, etoposide, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-24 15:55:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CuIlen-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-24 15:55:54 +0200" MODIFIED_BY="[Empty name]">
<P>Induction therapy with vincristine, adriamycin, cyclophosphamide after randomisation to further courses or no more chemotherapy. Patients received as second-line treatment the same chemotherapy regimen of first-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EarI-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Planned chemotherapy with cyclophosphamide, vincristine, etoposide versus chemotherapy given for tumour-related symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eridani-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Adryamicin, cyclophosphamide versus bleomycin, adriamycin, cyclophosphamide, oncovicin combination versus cyclophosphamide, vincristine, cisplatin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ettinger-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation to cyclophosphamide, doxorubicin, vincristine vs the same regimen alternating with hexamethylmelamine, etoposide, methotrexate. Incomplete response randomisation to maintenance chemotherapy versus observation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-07 20:54:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garassino-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-07 20:54:14 +0200" MODIFIED_BY="[Empty name]">
<P>Retrospective report of outcomes in SCLC patients following various regimens of second-line chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giaccone-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Induction cyclophosphamide, doxorubicin, etoposide. Incomplete or partial response randomisation to maintenance chemotherapy versus observation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cyclophosphamide vs placebo or nitrogen mustard versus placebo in previously treated patients with radiotherapy, surgical resection or previous chemotherapy not clarified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 20:33:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GrideIIi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 20:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of carboplatin, vinorelbine, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-08 11:26:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hainsworth-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-08 11:26:02 +0200" MODIFIED_BY="[Empty name]">
<P>Phase II study of paclitaxel, carboplatin, teniposide, etoposide, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-27 12:10:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanna-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-27 12:10:30 +0200" MODIFIED_BY="[Empty name]">
<P>Induction etoposide, ifosfamide cisplatin, and randomisation to oral etoposide or no further therapy in partial, complete or stable response</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-James-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cisplatin, etoposide, adriamycin, vincristine versus the same drugs at half the dose but twice the frequency</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joss-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Carboplatin, teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine, carmustine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-26 15:30:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kokron-1974a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-26 15:30:19 +0200" MODIFIED_BY="[Empty name]">
<P>Preliminary results of the study of Kokron 1977b. Same as Kokron 1974b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 20:41:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kokron-1974b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 20:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>Preliminary results of the study of Kokron 1977b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 20:42:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kokron-1977a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 20:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>Same as Kokron 1977b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 20:42:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korfel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 20:42:49 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of teniposide as second-line chemotherapy in relapsed SCLC</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lebeau-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Lomustine, cyclophosphamide, doxorubicin, etoposide plus aspirin versus same chemotherapy regimen. Incomplete response randomisation to same chemotherapy versus observation. Patients received more cycles of first-line treatment versus fewer cycles</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lyss-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of cisplatin, teniposide versus cisplatin, paclitaxel vs paclitaxel, teniposide versus paclitaxel teniposide at different doses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cyclophosphamide, vincristine, etoposide. Incomplete or partial response randomisation to interferon alfa versus cyclophosphamide, doxorubicin, cisplatin versus observation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cyclophosphamide, vincristine, etoposide. Incomplete or partial response randomisation to interferon alfa vs cyclophosphamide, doxorubicin, cisplatin versus observation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurer-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cyclophosphamide, methotrexate, vincristine pus cerebral irradiation vs cyclophosphamide. Incomplete response randomisation to further chemotherapy or observation. Patients received as second therapy more cycles of first-line chemotherapy versus fewer cycles</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:00:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mok-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>Phase I-II study of sequential administration of teniposide and oral etoposide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:00:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naka-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:00:48 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of irinotecan and carboplatin for relapsed SCLC</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noda-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Irinotecan, cisplatin versus etoposide cisplatin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:01:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reck-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of bleomycin, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:02:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenthal-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:02:31 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of epirubicin in recurrent SCLC, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schiller-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cisplatin, etoposide. No progression randomisation to topotecan versus observation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sculier-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Ifosfamide, etoposide, anthracycline. Incomplete or partial responses randomisation to maintenance chemotherapy with etoposide, vindesine versus no further chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:08:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smit-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:08:24 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of etoposide in SCLC patients older than 70 years, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Souhami-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Oral etoposide versus cisplatin, etoposide intravenous</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundstrom-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cisplatin, etoposide versus cyclophosphamide, etoposide, vincristine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 23:21:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tada-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 23:21:52 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of carboplatin etoposide in SCLC patients older than 76 years, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thatcher-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Oral etoposide versus etoposide, vincristine versus cyclophosphamide, adriamycin, vincristine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:11:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomas-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:11:47 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of CI-980, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tjan_x002d_He_x00ed_jnen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Cyclophosphamide, adriamycin, vincristine versus intensified same chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:13:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanseenkiste-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of gemcitabine, etoposide, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:14:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Pawel-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:14:31 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of etoposide, vincristine, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 21:15:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 21:15:01 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study of teniposide, cisplatin, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-02-28 17:58:20 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-21 18:47:26 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 20:33:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>There is no information data. Mentioned as multi-centre and probably randomisation made centrally. Patients randomly assigned 2:1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>The randomisation was conducted from the Institute of Cancer Research</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>The randomisation was conducted from the Institute of Cancer Research</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 20:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>Patients were randomly assigned 1:1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 21:01:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 21:02:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-05-13 21:02:55 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 20:35:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>There is no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 20:45:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 20:52:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 12:10:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>Centralised automated registration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-09 13:18:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-13 21:02:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-05-13 17:52:09 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-11-21 18:47:26 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Toxicity, tumour response, quality of life</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No information provided. Probably unblinded, but to determine survival it is probably not biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-13 20:35:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information provided. Probably unblinded, but to determine survival it is probably not biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-13 20:46:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information provided. Probably unblinded, but to determine survival it is probably not biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-11-21 18:47:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information provided. Probably partially blinded because a placebo infusion of Ringer's solution and Vitamin C was given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>No information provided. Probably unblinded, but to determine survival it is probably not biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-13 20:58:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-18 11:30:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-13 21:01:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided. Probably unblinded, but to determine survival it is probably not biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-13 21:03:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-05-18 11:32:45 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.09" NO="9">
<NAME>Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.10" NO="10">
<NAME>Tumour response, toxicity, quality of life</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2013-05-13 20:37:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No information provided. Probably unblinded. Outcome measure is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2013-05-13 20:38:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2013-05-13 20:46:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information provided. Probably unblinded. Outcome measure is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2013-05-13 20:47:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2013-05-13 20:53:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information provided. Probably unblinded. Outcome measure is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2013-05-13 20:54:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2013-05-13 20:58:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>No information provided. Probably unblinded. Outcome measure is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2013-05-13 20:58:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2013-05-18 11:32:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2013-05-13 21:01:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2013-05-13 21:04:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided. Probably unblinded. Outcome measure is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2013-05-13 21:05:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Tumour response, toxicity, quality of life</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-14 17:14:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No information provided in tumour response and lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-06-30 18:32:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No Information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-14 17:20:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information provided of patients lost to follow-up or toxic deaths</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-18 11:55:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No Information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-14 17:24:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information provided of patients lost to follow-up, toxic deaths. Tumour response is reported for extensive and limited disease combined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-18 11:56:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No Information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-13 21:00:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>Patients did not complete the study due to toxicity 9BSC, 13 topotecan, other 13 BSC</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-13 21:00:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-18 11:56:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-18 11:36:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>Patients lost to follow-up not provided. Relapse chemotherapy was not administered to 124 patients, 54 (37.5%) assigned to four cycles of first-line chemotherapy and 70 (47%) assigned to eight of first-line chemotherapy. No toxicity was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-05-18 11:57:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-30 18:32:11 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-30 18:32:11 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>Authors did not present all the information considered relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-14 17:21:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>Authors did not present results on all important outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-14 17:24:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>Authors did not present results in all important outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-07 20:52:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>Authors presented results on all outcomes measures that were pre-specified as relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-18 11:38:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-14 17:31:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>Authors did not present results on all outcomes measures considered relevant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-08-29 15:08:35 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-29 15:08:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ciuleanu-2010">
<DESCRIPTION>
<P>No information of baseline patient characteristics per group. Pharmaceutical sponsorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-18 12:09:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1977b">
<DESCRIPTION>
<P>No information of baseline patient characteristics per group. Statistical analysis inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-18 12:09:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kokron-1982">
<DESCRIPTION>
<P>No information of baseline patient characteristics per group. Statistical analysis inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-18 12:23:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2006">
<DESCRIPTION>
<P>The study appears to be free of other bias. Pharmaceutical sponsorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-18 11:39:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2007a">
<DESCRIPTION>
<P>Same as O'Brien 2006</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-18 12:11:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiro-1989">
<DESCRIPTION>
<P>No information of baseline patient characteristics per group at treatment with second-line chemotherapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-11-19 19:10:17 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-11-19 19:10:17 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-08-29 15:06:58 +0200" MODIFIED_BY="[Empty name]">First-line chemotherapy compared with BSC for extensive SCLC</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>First-line chemotherapy compared with BSC for extensive SCLC</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: patients</B> with extensive SCLC without previous treatment</P>
<P>
<B>Settings: one hospital in Vienna</B>
</P>
<P>
<B>Intervention: first-line chemotherapy</B>
</P>
<P>
<B>Comparison: Supportive treatment</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Supportive care</P>
</TH>
<TH VALIGN="TOP">
<P>First-line chemotherapy</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>The mean survival ranged across control groups from<BR/>56-93 days <SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean survival in the intervention groups was<BR/>134-172 days <SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>65 (2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>,2,3</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>Haematological: 0%</P>
<P>Leucopenia:0%</P>
<P>Vomiting and hair loss: 0%</P>
<P>Other: 0%</P>
</TD>
<TD VALIGN="TOP">
<P>Haematological:   94.1%</P>
<P>Leucopenia:15% ifosfamide; 15.8% ifosfamide + CCNU</P>
<P>Vomiting and hair loss: 70% ifosfamide; 68.4% ifosfamide + CCNU</P>
<P>Other: 55% ifosfamide; 52.6% ifosfamide + CCNU</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>65 (2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. The corresponding median survival time in extensive SCLC in the control and intervention groups has been obtained from Kokron 1977 and Kokron 1982</P>
<P>2. Significant risk of bias across the studies</P>
<P>3. Small sample sizes across the studies</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-11-14 13:02:20 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-03-01 19:14:05 +0100" MODIFIED_BY="[Empty name]">Second-line chemotherapy at relapse or progression in extensive SCLC</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Second-line chemotherapy compared with BSC for extensive SCLC</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: patients </B>with extensive SCLC who relapsed or progressed after first-line chemotherapy</P>
<P>
<B>Settings: multi-institutional-multicentre</B>
</P>
<P>
<B>Intervention: second-line chemotherapy</B>
</P>
<P>
<B>Comparison: BSC</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>BSC</P>
</TH>
<TH VALIGN="TOP">
<P>Second-line chemotherapy</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>The median survival ranged across control groups from 97.3-138 days<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The median survival in the intervention groups was 144-181.3 days<SUP>2</SUP>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>HR: 0.73</P>
<P>(0.55, 0.96)</P>
</TD>
<TD VALIGN="TOP">
<P>542</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low </B>
<SUP>4,5</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P>Toxic death</P>
</TD>
<TD VALIGN="TOP">
<P>0%</P>
</TD>
<TD VALIGN="TOP">
<P>6% topotecan</P>
<P>0% picoplatin</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>542</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate </B>
<SUP>4</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>Dyspnoea 3%</P>
<P>Fatigue 4%</P>
<P>Non sepsis infection 12%</P>
<P>sepsis 1%</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Haematological: 18%-61% neutropenia, 38%-41% Thrombocytopenia, 25%-29% anaemia,</P>
<P>Non sepsis infection 14%</P>
<P>Sepsis 4%</P>
<P>Asthenia 11%</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>542</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate </B>
<SUP>4</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P>Quality of life</P>
</TD>
<TD VALIGN="TOP">
<P>See footnotes 3</P>
</TD>
<TD VALIGN="TOP">
<P>See footnotes 3</P>
</TD>
<TD VALIGN="TOP">
<P>Difference in rate of deterioration per 3-month intervals in the EQ-5D score: 0.15 (95% CI 0.05, 0.25)</P>
<P>In the PSA questionnaire:</P>
<P>shortness of breath RR: 2.18 (1.09 to 4.38)</P>
<P>interference with sleep RR: 2.16 (1.15 to 4.06)</P>
<P>fatigue RR: 2.29 (1.25 to 4.19)<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>141</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>
<B>low </B>
<SUP>4,5</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>BSC:</B> best supportive care; <B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>HR</B>: hazard ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. The corresponding median survival time in extensive SCLC in the control group has been obtained from O'Brien 2006 and Ciuleanu 2010</P>
<P>2. The corresponding median survival time in extensive SCLC in the intervention group has been obtained from O'Brien 2006 and Ciuleanu 2010</P>
<P>3. The difference in rate of deterioration was obtained through the EQ-5D (EuroQol-5-Dimensions Health) questionnaire, consisting of five health status dimensions: mobility, self-care, usual activities, pain and discomfort, anxiety and depression, with rating of 1 (no problem) to 3 (extreme problem). Patients were evaluated before each course of second-line chemotherapy, or at each visit in the BSC arm.</P>
<P>The PSA (Patient Self Assessment) questionnaire rating scale for severity is from 1 (not at all), to 4 (very much)</P>
<P>4. Some significant risk of bias across the studies</P>
<P>5. Some significant risk of other bias in one study</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-11-19 19:07:16 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-11-19 18:53:14 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">First-line chemotherapy versus best supportive care (BSC)</TITLE>
<TABLE COLS="4" ROWS="3">
<TR>
<TD>
<P>Study</P>
</TD>
<TD ALIGN="CENTER">
<P>Group A</P>
</TD>
<TD ALIGN="CENTER">
<P>Group B</P>
</TD>
<TD ALIGN="CENTER">
<P>Group C</P>
</TD>
</TR>
<TR>
<TD>
<P>Kokron 1977b</P>
</TD>
<TD>
<P>Supportive care: mainly antibiotics and analgesics</P>
<P/>
</TD>
<TD>
<P>Ifosfamide monotherapy: 1500 mg/m<SUP>2</SUP> ifosfamide</P>
<P>as short infusion iv. on day 1, followed by ifosfamide</P>
<P>1000 mg/m<SUP>2</SUP> iv.on days 2 and 3. Repetition of ifosfamide</P>
<P>1000 mg/m<SUP>2</SUP> iv on days 8, 9, 10 and 15,16,17.</P>
<P>Continuation of the therapy after six weeks with three day therapy (1000 mg/m<SUP>2</SUP> daily each).</P>
</TD>
<TD>
<P>-------------------------------------------------</P>
</TD>
</TR>
<TR>
<TD>
<P>Kokron 1982</P>
</TD>
<TD>
<P>No active anticancer treatment: infusion of Ringers solution 1000 ml + 1 gr vitamin C iv three times a week during an in-patient stay.</P>
</TD>
<TD>
<P>Ifosfamide monotherapy: same schedule as the first study</P>
</TD>
<TD>
<P>Ifosfamide + CCNU (chloroethyl-cyclohexyl-nitrosourea):</P>
<P>ifosfamide therapy as described under Group B,</P>
<P>in addition to CCNU 60 mg/m<SUP>2</SUP> on day 1 with repetition after six weeks.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">Second-line chemotherapy at relapse versus best supportive care (BSC)</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TD ALIGN="CENTER">
<P>Study</P>
</TD>
<TD ALIGN="CENTER">
<P>Group A</P>
</TD>
<TD ALIGN="CENTER">
<P>Group B</P>
</TD>
</TR>
<TR>
<TD>
<P>Spiro 1989*</P>
</TD>
<TD>
<P>Symptomatic treatment including palliative irradiation</P>
</TD>
<TD>
<P>Methotrexate 50 mg/m<SUP>2</SUP> iv plus doxorubicin 50 mg/m<SUP>2</SUP> iv, repeated every</P>
<P>three weeks with a maximum of nine courses</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Brien 2006**</P>
</TD>
<TD>
<P>BSC<SUP>a</SUP>
</P>
</TD>
<TD>
<P>Topotecan in capsules containing the equivalent to 0.25 mg, doses</P>
<P>2.3 mg/m<SUP>2 </SUP>on days 1 to 5 every 21 days, at least four cycles + BSC.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciuleanu 2010***</P>
</TD>
<TD>
<P>BSC<SUP>a</SUP>
</P>
</TD>
<TD>
<P>Picoplatin 150 mg/m<SUP>2</SUP>, every 3 weeks median cycles 3</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Patients with disease progression. First-line chemotherapy treatment consisted of either four or eight cycles of cyclophosphamide 1 g/m<SUP>2</SUP> iv; vincristine 1.4 mg/m<SUP>2</SUP> iv; on day 1, and etoposide capsules 100 mg orally eight hourly on days 1 to 3, every 21 days</P>
<P>**Patients with relapse and who were unsuitable for further intravenous chemotherapy</P>
<P>***Patients with refractory disease or progression within six months after first-line platinum-based chemotherapy</P>
<P>a = Best Supportive Care</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-11-19 19:07:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">Results of the studies included in the review (first-line chemotherapy versus best supportive care (BSC)</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
<P>
<B>ID</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Objective</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Survival</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Tumour response</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Toxicity</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="MIDDLE">
<P>
<B>Kokron 1977b</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>To compare supportive care vs Ifosfamide</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>MST<SUP>1:</SUP> supportive care group = 93 days vs 172 Ifosfamide group (range:11 to 544 vs 1 to 1096)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>PR<SUP>2</SUP> = 0%  supportive care group vs 47% Ifosfamide group</P>
<P>CR<SUP>3</SUP>= 0%</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Haematological: 0%  supportive care group vs  94.1% Ifosfamide group</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="MIDDLE">
<P>
<B>Kokron 1982</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>To compare no active anticancer treatment vs ifosfamide vs Ifosfamide + CCNU</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>MST: in extensive disease: no active anticancer treatment = 56 days vs 134 Ifosfamide vs 122 Ifosfamide + CCNU. Grouped data: no active anticancer treatment, median = 161.5 (MST = 208.4), Ifosfamide, median = 341 (MST = 348.5), Ifosfamide + CCNU, median = 252 (MST = 322.3)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Grouped data (extensive and limited disease): CR = 1.9% Ifosfamide; PR = 16.9 Ifosfamide, and 13.2% Ifosfamide + CCNU</P>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Grouped data: leucopenia:0% no active anticancer treatment; 15% Ifosfamide; 15.8% Ifosfamide + CCNU. Vomiting and hair loss: 0% no active anticancer treatment, 70% Ifosfamide; 68.4% Ifosfamide + CCNU. Other: 0% no active anticancer treatment; 55% Ifosfamide; 52.6% Ifosfamide + CCNU</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>MST = mean survival time; PR = partial response; CR = complete response; CCNU = cyclohexylnitrosourea</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2013-11-14 13:01:34 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">Results of the studies included in the review (second-line chemotherapy versus best supportive care (BSC)</TITLE>
<TABLE COLS="6" ROWS="4">
<TR>
<TD>
<P>
<B>Study</B>
</P>
<P>
<B>ID</B>
</P>
</TD>
<TD>
<P>
<B>Objective</B>
</P>
</TD>
<TD>
<P>
<B>Survival</B>
</P>
</TD>
<TD>
<P>
<B>Tumour response</B>
</P>
</TD>
<TD>
<P>
<B>Toxicity</B>
</P>
</TD>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P/>
<P/>
<P/>
<P>
<B>Spiro 1989</B>
</P>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>To assess the effects of duration of chemotherapy on survival, <I>and </I>at relapse, the effects of further chemotherapy compared with symptomatic treatment</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>MST<SUP>1</SUP>: symptomatic = 77 to 84 days vs 140 to 105 days methotrexate-doxorubicin group (<I>in previous chemotherapy: 4 cycles-8 cycles, vs 4 cycles-8 cycles)</I> Only significant 77 vs 140 days (P &lt; 0.001)</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>PR<SUP>2</SUP> or CR<SUP>3 </SUP>in methotrexate-doxorubicin group = 22.3%</P>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Not provided for second-line chemotherapy</P>
<P/>
<P/>
<P/>
</TD>
<TD>
<P>-------------------</P>
</TD>
</TR>
<TR>
<TD>
<P/>
<P/>
<P/>
<P/>
<P>
<B>O'Brien 2006</B>
</P>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>To define risk and benefit of second-line chemotherapy at relapse vs BSC in patients unsuitable for standard intravenous chemotherapy</P>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>MST: in BSC 97.3 days (95% CI, 77.7 to 130.2) vs  181.3 days (95% CI, 128.1 to 221.2) in Topotecan group (log-rank P = 0.01)</P>
<P/>
<P>
<I>Subgroup analysis</I>
</P>
<P>a) <U>treatment-free interval &lt;=60 days of first-line chemotherapy:</U> topotecan 163.1 (95% CI 74.9 to 216.3) vs BSC 92.4 (95% CI 49 to 147)</P>
<P>b) <U>performance status 2</U>: topotecan 146.3 (93.8 to 188.3) vs BSC 53.9 (37.1 to 91.7)</P>
<P>c) <U>female</U>: HR 0.38 (95% CI 0.18 to 0.76)</P>
<P>d) <U>liver metastasis</U>: HR 0.58 (95% CI 0.38 to 0.88)</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>PR  in the topotecan group = 7% (95% CI, 2.33 to 15.67)</P>
<P>CR 0%</P>
<P/>
<P>In treatment-free interval &lt;=60 days: PR 18% (5.2 to 40.3) vs 2% 80.05 to 10.9) in treatment-free interval &gt;60 days</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Topotecan group: <I>Haematological</I>: neutropenia ¾, 61%; thrombocytopenia ¾, 38%, anaemia ¾, 25%. Nonsepsis infection&gt;= grade 2, 14%, vs 12% in BSC. Sepsis 4% in topotecan vs 1% in BSC.</P>
<P>
<I>Non-haematologica</I>l 3/4<SUB> </SUB>in topotecan vs BSC: dyspnoea 3% vs 9%; fatigue 4% vs 4%.</P>
<P>Toxic deaths in topotecan: 6%</P>
<P>all-cause mortality within 30 days: 7% topotecan vs 13% BSC</P>
</TD>
<TD>
<P>Difference in rate of deterioration per 3-month intervals in EQ-5D was 0.15 (95% CI 0.05 to 0.25)</P>
<P>In PSA questionnaire:</P>
<P>shortness of breath RR 2.18 (1.09 to 4.38)</P>
<P>interference with sleep 2.16 (1.15 to 4.06)</P>
<P>fatigue 2.29 (1.25 to 4.19)</P>
<P>All in favour of topotecan</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Ciuleanu 2010</B>
</P>
</TD>
<TD>
<P>To assess survival of patients treated with second-line chemotherapy who were refractory or who progressed within six months of first-line platinum-based chemotherapy</P>
</TD>
<TD>
<P>MST: in BSC 138 days (95% CI 112 to 168)</P>
<P>in picoplatin 144 days (95% CI 133 to 175)</P>
<P>HR: 0.817 95% CI 0.65 to 1.03 (P=0.00895)</P>
<P/>
<P>Time to progression:79 days picoplatin, 47 days BSC</P>
<P>HR: 0.610 (P=0.0002)</P>
<P/>
<P>Median progression-free survival: 63 days picoplatin, 46 days BSC</P>
<P>HR: 0.783 (P=0.0281)</P>
<P/>
<P>
<I>Subgroup analysis</I>
</P>
<P>a) <U>patients who did not receive chemotherapy post-study</U> (273: 194 picoplatin vs 79 BSC): picoplatin 128 days (95% CI 112 to 140), BSC 101 (77 to 140), HR 0.730 (P=0.0345)</P>
<P>b) <U>patients refractory or relapsed within 45 days of first-line chemotherapy</U> (294: 202 picoplatin vs 92 BSC):</P>
<P>picoplatin 149, BSC 129,</P>
<P>HR 0.717 (P=0.0173)</P>
<P/>
</TD>
<TD>
<P>No data provided</P>
</TD>
<TD>
<P>Picoplatin group: <I>Haematological</I>: 3/4 in &gt;10%:</P>
<P>44% thrombocytopenia</P>
<P>29% anaemia</P>
<P>18% neutropenia</P>
<P>&lt;1% febrile neutropenia</P>
<P>No deaths to haematological toxicity, no bleeding</P>
<P>
<I>Nonhaematological</I>:</P>
<P>0.8% grade 3 neuropathy</P>
<P>11% asthenia</P>
<P/>
</TD>
<TD>
<P>-------------------------</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>MST = median survival time; PR = partial response CR = complete response; BSC = best support care; CI = confidence interval; EQ-5D = EuroQol-5-Dimensions (mobility, self-care, usual activities, pain and discomfort, anxiety and depression) with rating 1 (no problem) to 3 (extreme problem); PSA = Patient Self Assessment questionnaire, with rating 1 (not at all) to 4 (very much)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Second-line chemotherapy at relapse versus best supportive care (BSC)</NAME>
<IV_OUTCOME CHI2="1.8787544187591938" CI_END="0.9634063718560377" CI_START="0.5505664208701139" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.7282988383872658" ESTIMABLE="YES" I2="46.77324561341866" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.01619048563964012" LOG_CI_START="-0.2591902798215922" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.13769038273061612" MODIFIED="2013-08-29 14:24:26 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17047599266018865" P_Q="1.0" P_Z="0.02634153082934724" Q="0.0" RANDOM="YES" SCALE="3.8931077665744143" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.019967695000000008" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.221139257158984">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Second-line chemoth</GROUP_LABEL_1>
<GROUP_LABEL_2>BSC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BSC</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0269854845353177" CI_START="0.6499708280674457" EFFECT_SIZE="0.8170132225347809" ESTIMABLE="YES" ESTIMATE="-0.2021" LOG_CI_END="0.011564305300526483" LOG_CI_START="-0.1871061348858209" LOG_EFFECT_SIZE="-0.08777091479264718" MODIFIED="2013-07-05 17:54:46 +0200" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.1167" STUDY_ID="STD-Ciuleanu-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="60.6626205598352"/>
<IV_DATA CI_END="0.8653316586278466" CI_START="0.43000537307818026" EFFECT_SIZE="0.6099977563111423" ESTIMABLE="YES" ESTIMATE="-0.4943" LOG_CI_END="-0.06281740709524705" LOG_CI_START="-0.36652611771430765" LOG_EFFECT_SIZE="-0.21467176240477734" MODIFIED="2013-03-21 17:36:40 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SE="0.1784" STUDY_ID="STD-O_x0027_Brien-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="39.337379440164796"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-11-21 18:47:27 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-11-07 13:26:36 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAQgCAYAAADMuNojAABu9klEQVR42uy9D2RVf/zH/yVJkokk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-11-21 18:47:27 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzkAAAFLCAMAAADCubLIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-11-21 18:47:27 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZYAAALkCAIAAACjmISWAAAokUlEQVR42u3dv44USdbG4ZKQEEYb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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Second-line chemotherapy at relapse versus BSC, outcome: 1.1 Overall survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqwAAACQCAMAAAD6O8n9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-07-03 08:23:02 +0200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-04-09 12:59:56 +0200" MODIFIED_BY="[Empty name]">Electronic searches</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-06 09:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>1.1 MEDLINE search using the following strategy (Ovid)</B>
</P>
<OL>
<LI>small cell lung cancer. mp</LI>
<LI>oat cell.tw</LI>
<LI>SCLC.tw</LI>
<LI>1 or 2 or 3</LI>
<LI>randomized controlled trial.pt</LI>
<LI>controlled clinical trial.pt</LI>
<LI>randomized controlled trials/</LI>
<LI>random allocation/</LI>
<LI>double-blind method/</LI>
<LI>single-blind method/</LI>
<LI>or/5-10</LI>
<LI>clinical trial.pt</LI>
<LI>exp clinical trial/</LI>
<LI>(clin$ adj25 trial$).ti,ab</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab</LI>
<LI>placebos/</LI>
<LI>placebo$.ti,ab</LI>
<LI>Random$.ti,ab</LI>
<LI>research design/</LI>
<LI>or/12-19</LI>
<LI>comparative studies/</LI>
<LI>exp evaluation studies/</LI>
<LI>follow-up studies/</LI>
<LI>prospective studies/</LI>
<LI>(control$ or prospectiv$).ti,ab</LI>
<LI>or/21-25</LI>
<LI>11 or 20 or 26</LI>
<LI>4 and 27</LI>
<LI>limit 28 to human</LI>
</OL>
<P>
<B>1.2 EMBASE search using similar strategy</B>
</P>
<P>1. small cell lung cancer.mp<BR/>2. oat cell.tw.<BR/>3. SCLC.tw<BR/>4. lung small cell cancer DE<BR/>5. 1 or 2 or 3 or 4<BR/>6. random$.ti,ab</P>
<P>7. factorial$.ti,ab</P>
<P>8. placebo$.ti,ab</P>
<P>9. (doubl$ adj blind$).ti,ab</P>
<P>10.singl$ adj blind$).ti,ab</P>
<P>11. assign$.ti,ab</P>
<P>12. allocate$.ti,ab</P>
<P>13. DOUBLE-BLIND PROCEDURE.sh</P>
<P>14. RANDOMIZED CONTROLLED TRIAL.sh</P>
<P>15. SINGLE-BLIND PROCEDURE.sh</P>
<P>16. or/6-15</P>
<P>17. symptomatic therapy only</P>
<P>18. palliative cancer therapy.DE</P>
<P>19. best supportive care</P>
<P>20. palliative therapy.DE</P>
<P>21. supportive therapy.DE</P>
<P>22. or/17-21</P>
<P>23. 16 or 22</P>
<P>24.  5 and 23</P>
<P>25.  ANIMAL/ OR NONHUMAN/ OR ANIMAL EXPERIMENT/</P>
<P>26.  HUMAN/</P>
<P>27.  26 and 25</P>
<P>28.  25 not 27</P>
<P>29.  24 not 28</P>
<P>
<B>1.3 Search of Cochrane Central Register of Controlled Trials (CENTRAL)</B>
</P>
<P>1. small cell lung cancer</P>
<P>2. OAT CELL</P>
<P>3. SCLC</P>
<P>4. 1 or 2 or 3</P>
<P>5. CONTROLLED CLINICAL TRIAL</P>
<P>6. RANDOM ALLOCATION</P>
<P>7. DOUBLE-BLIND METHOD</P>
<P>8. SINGLE-BLIND METHOD</P>
<P>9.  or/5-8</P>
<P>10. (ANIMAL NOT HUMAN)</P>
<P>11. 9 not 10</P>
<P>12.  CLINICAL TRIAL</P>
<P>13. (clin$ adj25 trial$).ti,ab</P>
<P>14. (( singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)). ti,ab</P>
<P>15. PLACEBO</P>
<P>16. placebo$.ti,ab</P>
<P>17. random$.ti,ab</P>
<P>18. RESEARCH DESIGN</P>
<P>19. or/12-18</P>
<P>20. 19 not 10</P>
<P>21. 11 or 20</P>
<P>22. 4 and 21</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2013-07-03 08:23:02 +0200" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;2 of second-line chemotherapy&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;5 RCT: 2 first-line chemotherapy, 3 second-line chemotherapy&lt;/p&gt;&lt;p&gt;1 quality of life&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;55&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records screened&lt;/p&gt;&lt;p&gt;55&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of records after duplicates removed&lt;/p&gt;&lt;p&gt;16,282: 12,328 Medline/Cochrane&lt;/p&gt;&lt;p&gt; 3,954 Embase&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of records identified through database searching&lt;/p&gt;&lt;p&gt;Medline/Cochrane Controlled Trials 12,343&lt;/p&gt;&lt;p&gt;Embase 3,954&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of additional records identified through other sources&lt;/p&gt;&lt;p&gt;0&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded&lt;/p&gt;&lt;p&gt;49&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;49, out for inclusion criteria&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>